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ABSTRACT
A new core-in-cup tablet manufactured from a novel adjustable punch, has 
been formulated and evaluated as to its ability to release various model drugs via a 
zero-order rate o f release. The new punch, with an inner adjustable rod that can be 
adjusted to produce cup-shaped tablets o f various thicknesses, was used to 
manufacture the core-in-cup tablets. These core-in-cup tablets were then evaluated as 
to their ability to  be manufactured on a tabletting press, and to  their ability to  release 
model drugs both in vitro and in vivo. After evaluating the effect o f various 
formulation factors on the compressibility and flow o f various directly compressible 
powder combinations via factorial design, a directly compressible combination o f 
10%w/w camauba wax in ethylcellulose was found to  produce the best cup tablets for 
the core-in-cup tablets. During the evaluation o f the rate o f release o f the model drugs 
caffeine (soluble), ibuprofen (insoluble), and theophylline (intermediate solubility), it 
was found that polyethylene glycol 6000 was the m ost suitable polymer for the 
ibuprofen core tablet, and acacia gum was the most suitable polymer for the caffeine 
and theophylline core tablets. All model drugs wore released in vitro from the core-in- 
cup tablets at a zero-order rate o f release. To obtain a controlled release o f ibuprofen 
over an 8 -1 2  hour period, addition o f 10%w/w polyethylene glycol 6000 was most 
applicable. For the caffeine and theophylline, addition o f 30%w/w acacia gum was most 
applicable. On subsequent evaluation o f the in vivo performance o f the core-in-cup 
tablet, it was found that theophylline was released and absorbed in beagle dogs at a 
rate that was more strongly correlated with a zero-order rate model, as compared to 
the release and absorption o f theophylline from core only tablets. The core-in-cup 
tablets produced is, therefore, a versatile zero-order release rate dosage form that is 
simple to produce.
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11. INTRODUCTION.
11 BACKGROUND TO  PR O JEC T.
One o f the major objectives o f pharmaceutical and pharmacological research is
the discovery o f new chemical entities with favourable therapeutic properties and
relatively low risks o f adverse effects. However, one o f  the major problems o f the
pharmaceutical industry today is the limited number o f new chemical entities which
have been approved on the worldwide market (W on Jun, 1995). Therefore, instead o f
the traditional approach for the discovery o f new pharmacologically active agents, the
strategy o f many pharmaceutical companies and research institutes is to  focus on the
development o f new drug formulations which achieve an optimal therapeutic effect not
solely by the drug itse lf but also by principles o f release and absorption (Ranade,
1991; Squire and Lees, 1992; Chien, 1990). In the traditional dosage forms and the so-
called sustained-release preparations, the drug input into the body is specified by the
amount o f the drug that could be sustained in the body. There are now delivery «
systems specified by the rate (a constant amount per time) at which they deliver the 
drug (Heller, 1993; Ritschel, 1992; Baneijee and Robinson, 1991; Steinijans, 1990). 
Therefore, rate-controlled drug delivery offers very promising perspectives to 
pharmacological and therapeutic applications, and industrial product development. 
Furthermore, the oral controlled-release drug delivery systems have the most appeal to 
patients since they improve compliance and therefore, are the most widely researched 
group o f drug delivery systems.
Oral controlled-release drug delivery has many advantages (Read and Sugden, 
1987). Controlled-release oral dosage forms are designed to  increase drug efficacy by 
eluding sub-therapeutic concentrations and diminish the incidence o f toxic side effects 
by smoothing out the peak blood levels. I f  different therapeutic effects are found at 
different drug levels, the stability o f steady state plasma concentrations permits the 
prescriber to  elect the desired effect/s (Urquhart, 1982; Goldman 1982). Drugs can be
2used that otherwise might cause a high incidence o f side effects. Thus, the use o f 
controlled-release forms gives greater accuracy in therapy. Less frequent dosage 
should lead to  greater patient compliance. Even in the most sophisticated clinical 
situations, the number o f patients who take their medication as prescribed who have 
serum concentrations within the optimal therapeutic range is extraordinarily low 
(Porter, 1969; Ayd, 1974; M arkus, 1976). I f  controlled-release forms allow patients to  
take drugs once or twice a day when they are at home instead o f three or four times a 
day, the likelihood o f skipped doses is likely to  be smaller. Oral controlled-release 
systems also allow drugs with very short action or low therapeutic windows to  be 
effectively used as oral systems. It is also believed that absorption rates are less 
dependant on luminal contents and can therefore be released in vivo according to  a 
pharmacokinetically rational rate.
There are however, a few disadvantages to  oral controlled-release drug 
delivery. The loss o f therapeutic effect may well be greater if  the patient were to  miss a 
dose o f a controlled-release formulation, than if  they wore to  miss a  dose o f  a  
conventional dosage form. The toxic effects o f accidental release o f the complete dose 
from a controlled-release formulation are also much greater than from a conventional 
form. This is because larger amounts o f drug are frequently given in the controlled- 
release forms. Therefore, drugs with narrow therapeutic concentration ranges should 
preferably not be formulated in a controlled-release form. There are however, a 
number o f exceptions where controlled-release systems have been produced from 
drugs that have narrow therapeutic ranges. Theophylline formulations are a notable 
exception. The most important limitation o f oral controlled-release therapy is that it 
could lead to  a greater fraction o f the dose not being absorbed. This would then reduce 
the systemic availability o f  the drug in some patients^Controlled-release dosage forms 
should also be avoided for delivering drugs that have a long elimination half-life and 
run the risk o f accumulation.
The benefit derived from the use o f controlled-release systems, however, far 
outweigh the disadvantages and is why they are such popular dosage forms.
3Controlled-release drug delivery systems are formulated in many different 
forms for a large range o f uses. They range from simple compressed matrix type tablets 
(Melia, 1991) to  highly sophisticated implantable bioresponsive pumps (Chien, 1990). 
Like the many different types o f delivery systems available they also vary in their 
routes o f controlled drug delivery. These range from the transdermal route 
(Danckwerts, 1991) through to  implantable I. V. routes (Danckwerts and Fassihi,
1991). The many different types o f controlled-release drug delivery systems, their 
routes o f administration, and mechanisms o f release have been widely reviewed in the 
literature in a wide variety o f journals (Braybrook and Hall, 1990, Chien, 1985; Chien, 
1989; Langer, 1980; Laurencin and Langer, 1987; Ranade, 1991; Szycher, 1986).
1.2. APPROACHES TO  ZERO -O RD ER RELEASE.
There are many oral drug delivery systems on the market currently that provide 
some type o f sustained or prolonged release o f an active drug. M ost o f the 
commercially available systems consist o f simple compressed matrices incorporating 
active drug homogenously mixed together with a hydrophillic polymer or mixture o f 
polymers (Ford et al., 1985; Korsmeyer et al., 1983; Gumy et al., 1982; Theeuwes, 
1981). The polymers are mainly cellulose derivatives o f which hydroxypropylmethyl 
cellulose (HPMC) is probably the most popular. These systems are usually simple to 
manufacture on a large scale and are mostly produced on a tabletting press. Because o f 
the shape o f the tablet (biconvex or disc) it is theoretically impossible for these tablets 
to  release the active drug from it at a zero-order rate. This is because as the system 
erodes (which is the case with most polymers) die surface area exposed to  the 
dissolution fluid continually decreases or the diffusion path that the dissolved drug has 
to  travel before release into the dissolution medium also increases. W hether the matrix 
releases drug via swelling control or erosion (or both), it is almost impossible to 
achieve a zero-order release (Langer, 1980). M ost o f these matrix-type tablets release 
drug according to  the Higuchi (Higuchi, 1963,1962) square root o f time kinetics 
(Rhine eta l., 1980; Hsieh eta l., 1983; Lapidus and Lordi, 1968; Ford e ta i, 1987).
4This is because there is a higher rate o f release o f drug at the start o f its release, which 
slowly decreases as time passes. A graph o f the square root o f time versus amount o f 
drug released, should be linear.
Two possible means o f altering the release kinetics from matrix systems have 
been used to  obtain a zero-order rate o f release o f drugs. These are, (1) by means o f 
altering the geometry o f the erodible matrix systems, and (2) manipulating the rate o f 
diffusion o f drugs from the drug delivery systems together with the rate o f erosion o f 
the drug delivery system.
1.2.1 M anipulation o f geom etry
Zero-order rate release o f drugs from matrix controlled release tablets can be 
achieved by means o f creating a system in which the drug is released from a  constant 
surface area o f constant drug concentration to the dissolution fluid, i.e. release from 
one side o f a flat tablet, slab, base o f a cylinder, or inwardly releasing hemisphere. A 
few systems have been fabricated in which all sides except a single flat side, have been 
coated with a  thin impermeable (to  the active drug) polymer or other coating. Hsieh et 
al. (1983) produced inwardly releasing hemispheres o f sodium salicylate in 
polyethylene, and bovine serum albumin in ethylene vinyl acetate matrices, which were 
coated w ith paraffin (fig. 1.1). The release o f drug from this system was th a t 
conducted in saline solution. Zero-order release for 60 days at a  rate o f  0,5 mg/day 
was achieved from the polymer matrices containing bovine serum albumin.
5CENTRAL HOLE
IMPERMEABLE DRUG AND
POLYMER POLYMER MATRIX
COATING
Fig, 1.1  Inwardly releasing hemisphere shown in section.
These systems however, are difficult to manufacture and consist o f a  
number o f intricate steps in their production. They first have to be moulded, and 
then dip coated, which is very difficult to automate and obtain effective quality 
control.
M ore recently, a  perforated biconvex coated matrix tablet has been 
produced that exhibits an in vitro constant release rate o f drug (Sangalli et at. , 
1993). The tablet consists of a  biconvex matrix tablet that is produced on a single 
punch tabletting press by means o f special punches that have the ability to 
compress the tablet with a central 4 mm hole in it. The perforated matrix tablet is 
then coated with a  drug impermeable polymer in a  conventional coating pan (refer 
to figure 1.2 below). Ethylcellulose is used to coat the tablet as it exploits the 
relatively unfavourable exposure of the inner surface o f the hole to the coating.
6CENTRE DRILLED 
HOLE
POLYMER MATRIX OUTER LAYER
Fig. 1.2 Perforated coated matrix tablet shown in section
They found by means o f visual inspection, that by gradually decreasing the 
plasticiser concentration, the production o f a  resistant, apparently continuous layer was 
limited to  the more exposed core surface, while an irregular and weak membrane was 
obtained on the inner part o f the hole. These coated perforated systems provided an 
approximate in vitro zero-order release o f metoprolol tartrate for about 16 hours.
From a theoretical point o f view, drug release from perforated coated cores should 
occur only through the central hole, and the release kinetics depends on the increases 
in the releasing area and on the lengthening o f the diflusional path. This o f course, 
requires that there is an appropriate balance o f the tw o processes in order to  achieve 
linear drug release. To balance the tw o is very difficult and each system is probably 
only applicable to  a specific drug. The system is also solely suitable to  soluble drugs. 
For the release o f the drug to  be consistent from tablet to  tablet, another method o f 
only coating the exposed surfaces o f the tablet will have to  be obtained. An irregular
7inner perforated hole will cause a variation in the release rate o f the drug between 
tablets.
M ore recently, Kim (1995) has produced a similar perforated tablet matrix 
without coating. The theory o f zero-order release is based on the fact that as the 
surface area o f the outer surface o f the 'donut'-shaped tablet is decreased due to 
erosion, the inner surface (hole) o f the tablet is increased due to erosion. I f  the two 
rates are balanced, and the surface area decreases on the outside at the same rate, a 
zero-order rate o f release is achieved. Again, the central hole must be drilled 
separately, and quite a lot o f drug and adjuvants are wasted. The system is also not 
applicable to  soluble drugs, which behave as if  in a normal disc-shaped matrix tablet.
Another solid compressible tablet that claims to  release drug at a  near zero- 
order rate o f release is the Geomatrix11 system which consists o f a  multilayer tablet in 
which one or two modulating barriers control the release o f the drag from a deposit 
core containing the active ingredient (Conte eta l., 1993). Figure 1.3 below illustrates 
the Geomatrix* system with its two possibilities.
IMPERMEABLE
BARRIER
SLOW RELEASE 
DRUG MATRIX
G EO M A TRIX ®  I
QUICK RELEASE 
COMPONENT
G EO M A TRIX ®  2
Fig. 1.3 Geomatrix* system
8The Geomatrix* is produced as a multi-layer tablet on a tabletting press and is 
very easy to  automate its production. It cannot however, release drug at a zero-order 
rate o f release since it consists o f a polymer matrix, which it is. Depending on the 
mechanism o f release, it will either constantly decrease its effective surface area o f 
release by erosion or increase the solvent penetration path. Theoretically it cannot 
release drug at a zero-order rate o f release.
Seta et al. (1988) prepared core-in-cup compressed tablets o f disc-shaped 
bilayer core matrices o f captopril and hydroxypropyl cellulose (HPC) surrounded on 
the bottom surface and circumference wall (the cup) with an inactive mixture o f 
ethylcellulose and camauba wax. The tw o layers o f the core contained different 
concentrations o f captopril. It was found that this type o f system released captopril in 
vitro at a zero-order rate over a period o f 3 to  6 hours. Shenouda etal. (1990) also 
prepared a similar core-in-cup type compressed tablet o f dyphylline in HPMC as the 
core matrix and poly(ethyloxazoline) polymer as the inactive cup. Again, this type o f 
system has the ability to  release dyphylline in vitro at a zero-order rate o f  up to  7 to  8 
hours. In both the above studies, the core-in-cup tablets were produced by means o f 
first compressing out the active core on a single punch tabletting press using round flat 
face punches to  form a disc. The disc was then placed by hand in the centre o f a larger 
round flat - faced punch in the die cavity o f the press, filled with the inert polymer 
mixtures, and then compression coated by hand at high pressure. To place the core in 
the centre o f the round flat punch called for careful and tedious placement and 
judgement. The problem with this compression - coated method is that it cannot be 
automated and does not produce an even, elegant tablet. Both these properties are 
needed for commercial production o f tablets.
1.2.1 M anipulation o f diffusion o f d ru g  and  erosion o f polym er
If  one can formulate a drug delivery system in which the rate that the drug 
diffuses from the drug delivery system, is balanced with the rate that the polymer used
9in the drug delivery system erodes, d im  it can release drug at a zero-order rate. The 
zero-order rate release profile in tnesc systems is postulated to  arise from increased 
drug release (decreased drug diffusion path) from a decreasing thickness o f polymer 
gel, thereby compensating for the decreasing surface area o f the eroding dosage form. 
These systems have been extensively studied by Baveja, Rango Rao and others (Baveja 
et a l, 1988a, 1988b and 1987; Devi et a i, 1989). Using a series o f soluble beta- 
blockers, they have shown that incorporating sodium carboxymethyl cellulose 
(NaCMC) into an HPMC matrix tablet reduced the initial "burst" o f drug release and, 
by optimising the ratios o f HPMC, NaCMC, and the active drug, the shape o f the 
dissolution profile could be changed from a "square root o f time" relationship to one 
where almost 100% drug was released via zero-order kinetics. It was also interesting 
that zero-order drug release was achieved throughout the entire 12 hour profile, 
notwithstanding a pH change from acid to  neutral conditions afro’ 3 hours. All tablets 
containing NaCMC, with or without HPMC, lacked an initial burst, and this effect may 
be a result o f the suppression o f swelling and dissolution o f thijianionic polysaccharide 
in the acid medium initially used. Z oo-order release was accomplished with swelling 
and erosion control o f the polymer matrix. The formulation involved mixing a  soluble 
beta-blocker with a combination o f HPMC and NaCMC, and then compressing it into 
a tablet. By optimising the ratio between the drug and the polymers, the rates o f 
advancement o f the swelling front into the glassy core and the attrition o f the rubbery 
state polymer were made equal so that the diffusional path length for the drug 
remained constant.
These systems unfortunately, are only applicable to  drugs that are readily water 
soluble, as they rely on solubilization and then diffusion out o f the matrix. It also seems 
likely that different combinations o f polymers would be applicable to  different drugs to  
match the rate o f  the advancement o f  the swelling front into the glassy core and the 
rate o f attrition o f  the swollen polymer.
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1.3 STATEM ENT O F PROBLEM .
Currently, traditional oral sustained-release drug delivery systems such as 
matrix tablets, microcapsules, hydrogel capsules and osmotic pumps do not lead to
v
optimal drug therapeutic conditions, or are difficult and expensive to manufacture. 
Therefore, a need exists for sustained-release preparations that release constant levels 
o f a wide variety o f drugs for a period o f approximately 12 hours at a zero-order rate. 
This drug delivery system must be relatively simple to  produce on a commercial scale, 
and be reproducible in its release pattern.
1.4 DELINEATION O F PRO BLEM .
For this study, a core-in-cup type tablet will be produced and evaluated. The 
core portion o f the tablet will first be produced as a  normal disc - shaped tablet. Then 
the cup portion o f the tablet will be produced by means o f  a novel punch with an inner 
adjustable rod. Finally, the core will be compressed with the cup to produce a core-in­
cup tablet (Refer to  figure 1.6 for the schematic production process).
In formulating an effective core-in-cup zero-order (constant release with time) 
oral sustained-release drug delivery system, the problems that need to  be solved are:
(1) The drug delivery system must release the active drug/s at a constant zero- 
order rate to  the GIT for approximately 8 to  12 hours (GIT transit time). The 
core must release drug at a zero-order rate o f release, and the cup portion o f 
the tablet must maintain its shape for the period o f release.
(2) M anufacturing the zero-order drug delivery system must be simple, 
reproducible, and relatively inexpensive.
(3) The drug delivery system must be applicable to a wide variety o f drugs.
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15 APPROACH TO  PRO BLEM .
This project will be approached from a pharmaceutical formulation point o f 
view and will consider all factors that are responsible for the optimization o f the drug 
delivery system. Whenever possible, the technique o f factorial design will be used. This 
technique allows one to  investigate many factors simultaneously, without having to  
investigate all possible combinations o f factors. It also allows one to  investigate 
interactions (different responses to  one variable depending on the value o f another 
variable) between variables. For example, if  one considers the release rate o f drug from
i
a tablet that contains varying concentrations o f polymer and that has b e a t compressed 
to  different hardnesses. From a theoretical point o f  view, one would expect the rate o f 
release to decrease proportionally as the concentration o f polymer in the formulation 
increased. Also, one would expect that the rate o f release would decrease as the 
hardness o f the tablet increased. Consequently, the tablet that contains the most 
polymer and that has been compressed to  the highest hardness, to  release drug at a 
rate that was proportionately lower than the rate o f release from a tablet with the 
lowest concentration o f polymer and lowest compression. There are however, times 
when this is not so. Sometimes there is an interaction between the tw o variables 
(concentration o f polymer and hardness o f compression) that could produce a tablet 
that does not behave according to  predicted theory. Perhaps, the high compression 
force decreases the effectiveness o f the polymer to  hold back the drug and hence 
results in a quicker than expected rate o f release. This type o f interaction, then needs 
to  be investigated further.
For this study, a standard tabletting top punch was adapted by the University o f 
the W itwatersrand Engineering Department, so that it compresses a tablet into a cup- 
shape o f 2 mm depth. This cup-shaped tablet is then compressed together with the 
active disc-shaped core tablet to  give a core-in-cup tablet o f perfect reproducible 
dimensions. Figure 1.4 illustrates this core-in-cup tablet. The adapted punch to 
produce the cup-shaped tablet is shown in Figure 1.5.
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Active drug cores o f various thicknesses (depending on the quantity o f active 
drug required) are compressed into flat 7 mm diameter disc-shaped tablets. Then the 
inactive cups (outside cup diameter o f 11 mm and inside cavity diameter o f 7,5 mm) 
are compressed into cup-shaped tablets with the adapted punch.
Impermeable carnauba wax/cthylcelluiose cup
Fig. 1.4 Schematic diagram o f core-in-cup tablet.
The inside cup cavity o f the cup tablet is 0,5 mm larger than the core tablet, so that the 
7 mm core tablet can easily slip into the cavity for subsequent core-in-cup 
compression. Once both the cores and the cups are compressed, the cores are placed 
inside the cups and fed into the tabletting press, equipped with 12 mm round flat 
punches, to  finally be compressed into a single core-in-cup tablet.
Drug/polym er matrix core
16 mm
73 mm
11 mm
Fig. 1.5 Sparkeroded top punch used to  produce cup shaped tablets
13
These slightly larger punches and die cavity o f 12 mm ensure that the 11 mm core-in­
cup tablets can easily be fed into the final die cavity. Figure 1.6 graphically describes 
the production procedure that will be used to produce the core-in-cup tablets to be 
used in this study.
1. Cup compression
timin
7,5mm
u _ r $
Upper
punch 4. Core-in-cup compression
] Die
,2tnm n  n  3. Core-in-Cup  r~l \  fitting
I2nm
K ■ ■ H
2. Core compression C 3
7mm
Upper
punch
Lower
punch
*  | * 1 1 l tzmm
Compressed
Core-in-cup
m i
Compressed
core
Lower
punch
Fig 1.6 Production process o f Core-in-cup tablets
14
The inactive cups and the active cores as well as the two being compressed 
together, can be accomplished automatically on a tabletting press. This tabletting press 
can be modified with a special feed shoe that feeds the cores into the cups and then 
feeds these into the die cavity to  be finally compressed together. It is also a very simple 
method using exceedingly few adjuvants, and is applicable to a wide variety o f drugs. 
Once it was proved that the use o f such an adapted punch was feasible in producing 
core-in-cup tablets, a new punch with an adjustable inner rod (refer to  figure 1.7 
below) was made by Holland Tabletting Science, UK for the subsequent experiments. 
This punch has the ability to  produce cup-shaped tablets o f different depths.
16 mm
B o d y
Fig.1. 7 New adjustable punch w ith an adjustable inner rod to  produce cup shaped 
tablets o f various depths
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Core-in-cup tablets o f caffeine, ibuprofen and theophylline as model drugs that 
represent a wide variety o f physicochemical properties such as solubility, pKa's, 
ionisation, etc., will be used to  assess the suitability o f such a drug delivery system. 
Caffeine will be used as an aqueous soluble model drug, and ibuprofen will be used as 
an aqueous insoluble drug. These two drugs will be used in the preliminary 
investigations and the in vitro analysis. Theophylline, as an intermediate aqueous 
soluble model drug, will be used in the final in vitro analysis and as the model drug for 
the in vivo release studies. The drugs will only to  be used as model drugs, and 
consequently the thesis will not cover the shelf-life stability o f  the core-in-cup tablets 
and any other stability determination. It will also not cover the purity determination 
and testing o f any o f the physicochemical properties o f  the drugs. The purity, particle 
size, and solubility as determined by the supplier will be accepted as stated on their 
labels. All necessary precautions will be taken to  protect the purity and stability (both 
physical and chemical) o f the model drugs throughout the research. Only one batch o f 
each model drug will be used, and therefore, it is not necessary to  determine the batch 
to  batch variation o f the formulations o f the active drug. However, any variation 
between formulations will be rigorously tested. The model drugs were chosen mainly 
for their difference in solubility in aqueous solvent, as it is the major differentiating 
property for drug release from the core-in-cup tablets and dissolution in GIT fluids. 
Another major reason for choosing caffeine, ibuprofen and theophylline, is that they 
are readily available and much is known about their physicochemical properties.
Theophylline was chosen as the model drug for the in vivo analysis, because:
(1) It is stable in the GIT and well absorbed at different regions o f the GIT.
(2) It interacts with very few adjuvants (Chow et al., 1993; Hussein and
Friedman, 1990).
(3) It is a good candidate for controlled-release formulations because o f its
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narrow range o f effective blood concentration and short elimination half-life 
(M itenko and Ogilvie, 1973; Zaske et a i, 1977).
(4) The absorption o f theophylline in dogs from sustained-release preparations 
can be easily measured using plasma concentration-time data (Koritz et al., 
1986;M cK iem ane/a/., 1981; Munday et al., 1991).
Some relevant physicochemical properties o f the model drugs used in this study 
(The Pharmaceutical Codex, 1994), are listed in table 1.1.
TABLE 1.1.
Relevant physicochemical properties o f model drugs.
Property Caffeine
(anhydrous)
Ibuprofen Theophylline
Empirical formula CgHjflN+Oj Ci3H 180 2 c 7h *n 4o 2
M olecular weight 194,2 206,3 180,2
Melting range °C 234-239 75-78 270-274
Solubility at 25 °C
Aqueous 1 in 60 insoluble 1 in 120
ethanol 1 in 130 1 in 1,5 1 in 80
chloroform 1 in 7 1 in 1 1 in 200
pKa at25°C 14,0 5,3 < 1 and 8,6
Stability Caffeine is Stable in Sensitive to
decomposed the absence light.
by solutions o f oxygen. Stable
o f strong in air.
caustic salts.
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1 6  OVERVIEW .
The first chapter o f this project contains the introduction to  the project and the 
rationale for the project. The introduction concisely describes the currently available 
sustained - release drug delivery systems and their formulation characteristics and 
finally defines the problem w ith current oral sustained - release drug delivery systems. 
The problem is then delineated, and lastly the approach and methodology o f the project 
is described.
The second chapter o f this project describes the development o f the cup 
portion o f the tablet. As it is critical that the cup portion o f the tablet remains intact 
throughout the GIT, as well as retain the ability to  be easily moulded into a cup shape 
that can receive the active core o f the tablet, the compression properties and flow 
characteristics o f ethylcellulose w ith various nonaqueous binders were investigated.
The effect o f (i) type o f binder, (ii) concentration o f binder, and (iii) particle size o f 
ethylcellulose on the direct compression and flow o f the powder blend were evaluated.
Once a suitable formula for the cup tablet was established, core-in-cup tablets 
o f caffeine and ibuprofen were formulated to  investigate the practical feasibility o f such 
a drug delivery system. Here, the use o f different grades o f 
hydroxypropylmethylcellulose (HPMC) in the core o f the tablets to  release drug from 
the core-in-cup tablets were investigated. For this experiment, a  model punch which 
produces a cup-shaped tablet o f 2 mm depth was used. Once it was proved that the 
core-in-cup system was practically feasible, a  new adjustable punch was made by 
Holland Tabletting Science, UK. For these experiments, caffeine (soluble) and 
ibuprofen (insoluble) were used as model drugs.
The penultimate experiment in this chapter evaluates the new adjustable punch 
in producing cups o f different depths. It is necessary that the cup portion is developed 
further to  be capable o f producing cup tablets that can vary in their ability to  
accommodate various concentrations o f active drug in the core portion o f the tablet.
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To evaluate the new punch, tests on (i) the effect o f depth o f cup, (ii) concentration o f 
binder, and (iii) hardness o f compression o f the cup portion o f the tablet, on the 
friability o f the cup and its ability to  prevent splitting when using HPMC as the core 
tablet polymer, were conducted. Ibuprofen was used as the model drug for this 
investigation.
As the HPMC used in the previous studies swells when it comes into contact 
w ith dissolution fluid, the final experiment in the chapter investigated the effect o f 
processing variables on the release o f ibuprofen and caffeine from controlled release 
nonswellable core-in-cup compressed tablets. In this experiment, the effect o f (i) type 
o f polymer, (ii) concentration o f polymer, and (iii) hardness o f  compression o f the core 
tablet on the maximum time o f constant release o f caffeine and ibuprofen were 
investigated. The purpose o f the experiment therefore, was to  test the effectiveness o f 
nonswellable polymers in producing the core o f a core-in-cup tablet that does not swell 
to any appreciable extent when it comes into contact with aqueous dissolution fluid. 
The second major aim o f the experiment was to  optimise the formulations so that they 
could release drug constantly over a period o f at least 8 hours.
Chapter three, the formulation and in vitro evaluation o f the new sustained- 
release drug delivery systems was begun. Based on the previous investigations, the 
effectiveness o f the core-in-cup tablets to  release theophylline at a zero-order rate in 
the presence o f sequenced simulated gastrointestinal fluids was examined. The core-in­
cup system was also evaluated to  see if  it would be unaffected by the conditions in the 
simulated GIT fluids and whether it was capable o f releasing theophylline drug over a 
period o f at least 8 hours at a  zero-order rate.
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Chapter four deals with the in vivo analysis o f the core-in-cup tablet. Three 
different formulations o f theophylline were tested in Beagle dogs. These were,
(i) Core-in-cup tablet.
(ii) Core only tablet.
(iii) Immediate release capsule.
The formulations were tested to  determine if  the core-in-cup tablet released 
theophylline at a  zero-order rate o f release, and to  test whether it had any in vivo 
advantages over the core only control tablet. The dogs were dosed with immediate 
release capsules in order to  determine the elimination rate o f theophylline in each dog. 
The percentage area under the curve fluctuation at steady state was also calculated and 
compared for the different formulations.
In chapter five, the suitability o f the new core-in-cup controlled-release tablets 
are assessed and recommendations are made for the optimization o f such delivery 
systems for future studies.
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2.0 DEVELOPMENT OF THE CUP PORTION OF 
THE CORE-IN-CUP TABLET.
In this section o f the experimental part o f the thesis, the cup portion o f the 
core-in-cup tablet is investigated. Only once a  suitable cup portion o f the tablet is 
developed can the core and the rest o f  the tablet be developed. Since the cup portion 
o f the tablet and its production process is the novel part o f the tablet, much o f  the 
emphasis will be placed on this process.
2.1 TH E EFFEC T O F PRO CESSIN G  VARIABLES ON CO M PRESSION AND 
FLO W  PR O PER TIES O F VARIOUS D IRECTLY  CO M PRESSIBLE 
ETHYLCELLULOSE/NONAQUEOUS BIN D ER COM BINATIONS.
2.1.1. In troduction
In order to manufacture and formulate a core-in-cup tablet, it is essential that 
the cup portion o f the tablet adheres to the following criteria:
(i) The cup tablet must not disintegrate in its passage through the GIT. Therefore, the 
cup should be essentially hydrophobic.
(ii) The tablet must be produced on a tabletting press and therefore must not, cap, 
laminate, pit, or stick during compression.
(iii) It is also preferable that a directly compressible tabletting base be used so that cost 
and time savings with such systems is taken advantage of.
With the above criteria in mind, it was decided that a low viscosity grade o f
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ethylcellulose will be used as the directly compressible tabletting base. Ethylcellulose is 
an inert, hydrophobic polymer which has been widely used as a tablet excipient (Muti 
and Othman, 1989; Goodhart et al. , 1984; Shaikh et al., 1987). It is also a  good 
directly compressible base, and has been used recently in a  number o f direct 
compression applications (Katikaneni et al. 1995; Upadrashta et a l 1994; Upadrashta, 
1993; Nesic, 1987)
Although ethylcellulose itself is used as a  binder, and it compresses well into a 
compact mass, the unusual shape o f the cup tablet and its need for subsequent further 
recompression into a core-in-cup tablet, require the addition o f  an effective binder 
which can also add plasticity properties to  the ethylcellulose. In order for the cup 
portion o f the tablet to  remain insoluble in the aqueous environment o f the GIT, one 
cannot use normal binders which are soluble in aqueous fluid. This would lead to  the 
premature disintegration o f the cup portion o f the core-in-cup tablet. Accordingly, one 
needs to find suitable nonaqueous binders. Very little information is available on the 
use and availability o f nonaqueous binders. Dicalcium phosphate may be the only 
traditional binder that is insoluble in water. High melting point waxes could also 
possibly be used as binders. These waxes should also increase the plasticity o f the 
ethylcellulose base.
The purpose o f this part o f the study therefore, was to  test the effectiveness o f 
low viscosity ethylcellulose together with various binders in producing an effective 
cup-shaped tablet. Thus, it was decided to  preliminarily test the compressibility o f 
various nonaqueous binders and select the three best ones for further study. Secondly, 
it was decided to  examine the processing variables o f type o f binder (t), concentration 
o f binder (c), and particle size range o f low viscosity ethylcellulose (s) on the 
compressibility and flowability o f the powder blends. This study then results in a 33 
factorial design. The dependencies were explained using analysis o f variance and 
multiple regression analysis.
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A glidant/lubricant was not used in this study, because it is known to adversely 
affect the tablet strength (Bolhuis e ta l, 1995, Jarosz and Parrott, 1984; Shah etal., 
1986; Katikaneni et al., 1995). The mechanism o f such decrease is thought to  be due 
to the finer lubricant particles coating the larger excipient and drug particles and 
interrupting interparticulate bonding. Fragmentation o f brittle particles results in large 
areas o f new unexposed surfaces reducing the detrimental effect o f a lubricant on tablet 
strength. Ductile deformation does not produce the same extent o f new particle 
surfaces and the tablet strength o f ductile materials is typically more sensitive to 
lubricants. The effect o f lubricant on the compressibility, was confirmed in a 
preliminary study on the compressibility o f ethylcellulose containing 0,5%w/w 
magnesium stearate. It was found that when magnesium stearate was added to  the 
ethylcellulose, the resultant cup tablets began to  show signs o f capping. Once the 
magnesium stearate was removed, the tendency to  cap disappeared. The low viscosity 
ethylcellulose flows very well on its own and therefore it does not really need a glidant.
Many techniques are available to  characterise the compression behaviour o f 
powders and granules. These techniques include tablet hardness-compression force 
profiles (Higuchi, 1953; Fell and Newton, 1968), ejected tablet Heckel analysis 
(Heckel, 1961a,b), work calculations from force-displacement data (De Blaey eta l., 
1971; Krycer et al., 1982), and force-time profile analysis (Chilamkurti et al., 1983; 
Hoblitzell and Rhodes, 1990; M artinez-Paracheo et al., 1990). O f the above methods, 
the hardness-compression force profiles method is probably the most useful and 
simplest method to  characterise compressibility.
Although hardness is not a  central property, diametral crushing (hardness) is 
most typically used for in-process control and preformulation investigation o f new 
powder or granule blends or formulations (Parrott, 1990). There is a linear relationship 
between tablet hardness and the natural logarithm o f compression force (except at very 
high pressures). Plots o f natural logarithm o f compression force versus hardness are 
exponential in nature.
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Therefore, a plot o f tablet hardness versus the natural logarithm o f compression force 
results in the following hardness-compression profile over the linear portion o f the 
plot:
Fc = n ln P  + I -equation 2.1.1
where, Fc = Hardness o f tablet as measured by the diametral crushing 
strength.
P = Applied pressure as a measure o f compression force, 
n = slope o f the linear portion o f the plot.
I = intercept on the y-axis.
The two constants n and /  are indirect measures o f the compressibility o f the 
powder mix. As the slope o f the graph («) increases, then it can be said that the 
powder mix has an increased ability to  be compressed into a more compact mass and 
therefore has a better compressibility. The constant 1 is a measure o f the inherent 
compressibility o f a powder mix. Since the purpose o f this part o f the research is to 
estimate the compressibility o f various mixtures o f ethylcellulose and nonaqueous 
binders, it would be preferable to use a single parameter that best describes the 
compressibility. Factorial estimation also requires that a single parameter is used to 
estimate the effects o f various changes in the parameters. Therefore, it was decided 
that the slope n was the most suitable measure for estimating the compressibility o f the 
various powder mixtures.
As the proposed dry binders to  be investigated are waxy o r insoluble 
compounds, it is necessary to check the effect o f the binders on the flow properties o f 
the various powder mixes. Solid particles attract one another, and forces acting 
between particles when they are in contact are predominantly surface forces.
Therefore, the action o f the binder would be expected to  adversely affect the flow 
characteristics o f the directly compressible powder mix. Many methods are available to
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measure the extent o f interparticulate forces. Such measures are then commonly 
employed as an index o f flow. Some o f the more common methods that are used are (i) 
angle o f repose (Carstensen and Chan, 1977; Hiestand, 1966; Jones and Pilpel, 1966), 
(ii) shear strength determinations (York, 1975; Hiestand and Peot, 1974), and (iii) 
hopper flow rate measurements (Danish and Parrott, 1971; Gold et a l,  1968). The 
angle o f repose method is the simplest method and is suited to  particles that are larger 
than 150 pm (Gordon et a l,  1990). Briefly, the angle o f repose is a measure o f the 
ability o f an object to  overcome sliding when the angle o f inclination is large enough to 
overcome frictional forces. The method consists o f allowing a  powder mix to  flow 
through an orifice under the influence o f gravity and allowing it to  heap on a flat 
surface. The angle incident to  the surface is then the angle o f repose.
2.1.2. M aterials and M ethods
2.1.2.1. Materials
The low viscosity (45 cps at 25 °C in 80:20 toluene:ethanol) ethylcellulose with an 
ethoxy content o f 48,5% was supplied by Sigma Chemical Company, U S. A. The 
EmcompressR (dibasic calcium phosphate dihydrate supplied by Edward M enddl 
Company, Inc., U.S. A.), Suppocire C NA -1 0  (hydrogenated castor oil supplied by 
Gattefossd, s.a., France), hard paraffin (Saarchem, Pty., Ltd., R .S.A .), cetostearyl 
alcohol (Saarchem, Pty., Ltd., R .S.A .), and cetyl alcohol (Saarchem, Pty., Ltd.,
R.S.A .) were all ground in a m ortar and the fraction passing through a 355 pm 
aperture sieve (Endcotts Test Sieves, L td., London, England) was used.
2.1.2.2. Study design
The study followed a sequential l 1 preliminary study followed by 33 factorial 
experimental design. In the preliminary experimental phase, the ethylcellulose in the 
size range o f 600 pm to 850 pm was mixed with two different concentrations o f the 
various nonaqueous binders to be tested for compression and flow properties. Once
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the three most suitable binders were found, a 33 factorial design study was conducted. 
The amount o f binder added to  the ethylcellulose (c), particle size range o f 
ethylcellulose ip), and type o f binder (/), were used as independent variables. Type o f 
binder and its concentration, together with the average particle size o f the directly 
compressible tabletting base are the most critical factors in the compressibility and flow 
o f the powder blend. The normalized factor levels o f the independent variables are 
presented in table 2.1.1.
In the c and s  central points on each level o f t, and the 23 factorial points, the 
powder mixes were made in duplicate batches. Therefore, the total number o f runs was 
38. The compressibility and flow estimates were the dependant variables.
TABLE 2.1.1
Levels o f independent variables fo r  flow  and compressibility studies.
Variable
-1
Factor level 
0
Units
1
Concentration o f 
binder (c) 2 4 6 %w/w
Type o f binder if) Encom- Cetyl 
press alcohol
Camauba
wax
Particle size pm 
(± class mark in range) 
o f ethylcellulose (s) 475 725 975 pm
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2.1.2.3. Formulations
For the preliminary study on the suitability o f the binders, 15g o f the powder 
blends listed in table 2.1.2 were prepared. The low viscosity ethylcellulose and binders 
were used as supplied and blended in a  cube-shaped blender for 5 minutes. Table 2.1.2 
lists the results o f the preliminary study on the flow and compressibility o f the various 
nonaqueous binders investigated. As far as compressibility is concerned, hard paraffin 
has the best compressibility as signified by the steepest slope value. It is then followed 
sequentially by cam auba wax, EmcompressR and cetyl alcohol. The Suppocire C NA- 
10 exhibited sticking and pitting, even at low  compression forces o f 2,5 tonnes, and 
was therefore deemed not suitable as a  directly compressible binder. When analysing 
the flow properties o f the powder blends, EmcompressR was the best, followed in 
ascending order by Suppocire C NA-10, cam auba wax, cetyl alcohol, and hard 
paraffin. Hard paraffin exhibits by far the w orst angle o f repose, at a value o f  S5,81 ± 
7,42 and is therefore, not suitable as a binder for directly compressible tablets.
TABLE 2.1.2.
Angle o f repose and compressibility o f 5% Vw binders in the preliminary powder 
blends
Type Flow ± S.D. Compressibility ± S.D.
(Angle o f (slope o f
repose) graph) r2
(n=3) (n-3)
Camauba wax 37,45 ±3,31 * 30,62 ± 8,89 ## 0.873
Cetyl alcohol 46,29 ±6,51 14,57 ± 6 ,0 9 # 0,968
EmcompressR 34,51 ±4 ,67  * 23,51 ± 7 ,0 3 # # 0,823
Hard paraffin 55,81 ± 7,42 38,76 ± 6 ,24  # 0,944
Suppocire CNA-1 34,67 ± 8,36 * Pitting
(
N/A
* * in a  vertical column indicate homogenous groups that show no significant 
difference at the 95% confidence level using the LSD analysis o f variance test.
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Therefore, based on these preliminary results, it was decided that camauba wax, 
EmcompressR, and cetyl alcohol should be investigated further.
Once it was established that cetyl alcohol, EmcompressR and camauba wax, 
were the m ost suitable with respect to  flow and compressibility, Sg o f each powder 
mix as lifted in table 2.1.3 were prepared and tested for compressibility and flow 
properties. The ethylcellulose (mean particle size o f 418,84 pm ± S.D. o f287,31) was 
separated into three different size fractions by passing the powder as supplied through 
a nest o f sieves (Endcotts Test Sieves, Inc., London, England) with aperture sizes o f 
1000 pm, 850 pm, 600 pm, and 355 pm. These sieves were arranged in descending 
order o f size in an Endcotts Octagon 200 test sieve shaker, and the powder was shaken 
for 15 minutes at an amplitude o f 6. Before blending the fractions o f ethylcellulose 
with each o f the binders, the binders were first ground in a m ortar and the fraction 
passing through a 355 pm sieve was used. Each powder blend to  be tested was then 
mixed together with the specific binder to  be used, for 3 minutes in a  rotating cube 
blender and then tested, first for its flow, and then its compression properties.
2.1.2.4. Measurement ofpowder flow
The flow o f the powder blends were characterised from their angle o f repose 
measurements. This was measured by means o f lightly packing 5g o f each formula into 
a hollow glass cylinder (8 cm long with an internal diameter o f 22 mm) resting on a 
piece o f graph paper. The cylinder was then lifted vertically through a circular guide 
connected to a retort stand, and the powder was allowed to  heap on the graph paper.
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The radius and height o f the powder heap were then measured and the angle o f 
repose was calculated from the following equation;
<j) = arctan H  - equation 2.1.2
R
where, <|> = angle o f repose
H  = height o f powder heap 
R  = radius o f powder heap
In order to  measure the height o f the powder heap without disturbing it, the 
distance form the bottom  o f the cylinder guide to  the tip o f the powder heap was 
measured, and this value was subtracted from the distance from the bottom o f the 
cylinder guide to  top o f the bench.
2.1.2.5, Measurement o f compressibility
After measuring the angle o f repose, 700mg o f each powder mix was 
compressed to either 2,5 tonnes, 5,0 tonnes, or 7,5 tonnes 
in a Beckman hydraulic press (Beckman Instruments, Inc., Fullerton, U.S.A.). The 
tablets were compressed into flat 13 mm diameter round disc tablets for 10 seconds at 
each compression force. After standing for 30 minutes, the hardness o f the tablets were 
measured in a Pharma Test PTB 311 (Pharma Test, Hamburg, Germany). The slope o f 
the graph o f hardness (diametral crushing strength) o f the tablets versus natural 
logarithm o f compressional force was calculated using linear regression analysis. The 
slope was then used as the estimation o f the compressibility o f the powder blends 
tested.
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TABLE 2.1.3.
Angle o f repose and compressibility o f powder blends (t, type o f binder; s, particle 
size o f ethylcellulose; c, concentration o f binder) Subscripts a and b indicate 
replicates.
Run t s c Flow Compressibility r2
la -1 -1 -1 28.76 10.90 0,860
lb -1 -1 -1 35.15 10.77 0,966
2 -1 -1 0 34.77 17.38 0,998
3a -1 -1 1 47.95 23.98 0,874
3b -1 -1 1 50.77 28.27 0,998
4 -1 0 -1 30.27 2.90 0,884
5a -1 0 0 36.86 19.25 0,997
5b -1 0 0 41.71 17.21 0,966
6 -1 0 1 48.52 23.39 0,993
7a -1 1 -1 35.10 29.77 0,896
7b -1 1 -1 43.23 27.15 0,854
8 -1 1 0 39.35 20.13 0,998
9a -1 1 1 44.27 17.38 0,998
9b -1 1 1 48.70 28.35 0,888
10 0 -1 -1 26.67 22.40 0,917
11 0 -1 0 30.26 25.42 0,998
12 0 -1 1 33.32 49.77 0,897
13 0 0 -1 27.27 26.91 0,966
14a 0 0 0 30.21 33.65 0,946
14b 0 0 0 28.25 26.01 0,786
15 0 0 1 33.20 25.20 0,810
16 0 1 -1 26.29 40.15 0,993
17 0 1 0 29.29 28.52 0,968
18 0 1 1 31.91 59.35 0,984
19a 1 -1 -1 30.08 30.61 0,823
19b 1 -1 -1 28.78 34.43 0,658
20 1 -1 0 34.67 30.39 0,944
21a 1 -1 1 35.49 34.11 0,991
21b 1 -1 1 31.28 36.43 0,935
22 1 0 -1 31.18 57.00 0,996
23a 1 0 0 33.15 34.30 0,966
23b 1 0 0 28.45 44.23 0,888
24 1 0 1 34.19 70.41 0,919
25a 1 1 -1 23.28 25.18 0,993
25b 1 1 -1 28.56 24.87 0,990
26 1 1 0 26.93 48.43 0,968
27a 1 1 1 28.17 55.57 0,971
27b 1 1 1 34.13 50.66 0,854
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2.1.2.6. Statistical analysis
Analysis o f variance was performed on the data presented in Table 2.1.3 using 
STATGRAPHICS v 5 (Statistical Graphics Corporation, U .S.A.).|lhe^independent 
variables were % binder in the tablet, type o f binder used in the tablet, and the average 
particle size (as the class mark in the particle size range) o f the ethylcellulose. Because 
STATGRAPHICS requires that continuous variables are spaced equally apart for 
calculating the various outputs, the normalised values o f the class mark particle size 
within each size range were 475 pm, 725 pm, and 975 pm instead o f the actual values 
o f477,5 pm, 725 pm, and 925 pm. The actual class mark values were obtained 
because o f the unavailability o f350 pm and 1100 pm sieves. As we are only using the 
factorial design to estimate the effects o f each variable, this adjustment is quite in order 
for the analysis. The dependent variables were flow (through angle o f repose) and 
compressibility.|Response-surface plots were constructed for the above variables, in 
order to  determine the optimal combination o f the variables. M ain effects and 
significant interactions were also calculated. Simple regression models for the three 
independent variables were also developed from the results as follows:
Y, (c,t,s) =  a0 + a fi  + a f  + ays + a f i t  + a fis  + afis + afi2 + afi2 + afi2 a, fits
-equation 2 .13
where a(>...,a[0 are the coefficients o f the system, c, t and s  denote the % binder, type 
o f binder and particle size range o f the powder blends, respectively.
Each term in the final regression equation for the flow o r the compressibility 
was only included if  the r-test p  value was less than 0,05. The regression coefficients 
for those effects that were considered insignificant were eliminated and the model was 
re-estimated. All statistical analysis was performed using STATGRAPHICS v 5 
(Statistical Graphics Corporation, U.S.A.).
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2.1.3. Results and Discussion
Table 2.1.4 lists the relevant statistical parameters calculated from the results o f 
this study for the effect o f the three independent variables on the compressibility and 
flow o f the powder blends analysed. All statistical analysis was carried out on all the 
experimental runs.
2.1.3.1. Powder flow
Figures 2.1. la  - c are response surface plots o f the estimated effects o f the type 
o f binder, the % concentration o f binder, and the particle size o f ethylcellulose on the 
angle o f repose o f the powder blends. The plots have been drawn on the basis o f the 
model by assigning a constant value to  one o f the variables. All three variables play a 
statistically significant role in the resultant angle o f repose o f the powder blends. Type 
o f binder used in the powder blends has the most significant influence on its angle o f 
repose (Fig. 2.1. la  and 2.1. lb). This is particularly more pronounced with cetyl 
alcohol (Fig. 2 .1.1a). Cetyl alcohol has by far the worst effect on flow (through a 
larger angle o f repose), especially at higher concentrations (Fig. 2.1. lb). There is a 
similar effect on the flow o f the powder blends that incorporate EncompressR and 
camauba wax. Encompress* has a slightly lower angle o f repose value on average over 
the various particle size ranges and concentrations o f each binder used.
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Relevant statistical parameters fo r  flow  and compressibility studies
TABLE 2.1.4.
Source Estimated effects p -value Regression Regression
effect ± standard error coefficients coefficients
(28 d f ) re-estimated
Angle of repose
average
constant
29,211 ± 1,185
29,211 29,667
t -9,789 ± 1,084 <0,0001 -4,894 -4,894
s -0,404 ± 1,126 0,7262 -0,202
c 8,388 ± 1,126 < 0,0001 4,194 4,194
ts -3,251 ± 1,283 0,0172 -1,626 -1,626
tc -4,808 ± 1,283 0,0008 -2,404 -2,404
sc -2,041 ± 1,283 0,1230 -1,021
tt 11,225 ±2,134 < 0,0001 5,613 5,700
ss -1,089 ±2,087 0,6115 -0,544
cc 2,608 ± 2,087 0,2218 1,304
Compression
average
constant
31,849 ±4,229
31,849 31,338
t 21,414 ±3,872 < 0,0001 10,707 10,707
s 7,742 ±4,018 0,0642 3,871
c 12,295 ±4,018 0,0048 6,147 6,147
ts 0,726 ±4,581 0,8769 0,363
tc 3,521 ±4,581 0,4567 1,761
sc 0,074 ±4,581 0,9874 0,037
tt -7,235 ± 7,619 0,3605 -3,612
ss -2,774 ± 7,450 0,7163 -1,387
cc 9,072 ± 7,450 0,2335 4,536
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As the concentration o f binder in the powder blends increase, the angle o f 
repose increases (Fig. 2.1.1b and 2 .11c) This increase in the angle o f repose is most 
prominent with cetyl alcohol (Fig. 2.1. la ) and with a combination o f smaller average 
particle size and higher concentration o f binder (Fig. 2.1.1c). This is evidenced from 
the significant tc statistical interaction. Since the cetyl alcohol is a  waxy binder, this 
adverse effect on the flow o f the directly compressible powder blend is expected. 
Surprisingly, the effect o f particle size o f  the ethylcellulose used in the powder blends 
is not statistically significant, and there was very little difference in the angles o f repose 
over the various size ranges tested (Fig. 2.1.1a and 2.1. lc). However, as the 
concentration o f binder used increased, the effect o f increase in particle size on the 
angle o f repose becomes a little more pronounced. At lower concentrations o f binder, 
the opposite occurs (Fig. 2.1. lc).
In developing a regression model for the effect o f the independent variables on 
the angle o f repose dependent variable, the main effects o f type o f binder (/) and 
concentration o f binder (c) as well as the second order interaction effects o f ts, tc and 
tt were significant (p < 0,05). Therefore, the regression coefficients for these effects 
were included in the model. The rest o f the coefficients were eliminated and the model 
was re-estimated by STATGRAPHICS.
Yf (t,p,c) = 29,66 - 4,894t + 4,194c - l,626ts - 2,404tc + 5,700tt
-equation 2.1.4
where Yf (t,p,c) is the estimated angle o f repose o f the powder blends.
The squared multiple regression coefficient for this model was 0,87. This 
model shows that the type o f binder has the major adverse effect on the friability o f the 
cup tablet. Cetyl alcohol (signified by 0 on the type axis o f the response surface plots 
in figure 2 .1 .1 a  and b) is by far the w orst for flow properties, which is then followed 
by EncompressR, and thereafter by camauba wax. The concentration o f  binder then 
produces the next most significant effect on the angle o f repose.
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Type
Fig. 2.1.1 a Response surface plots of the estimated effects of t and s on the angle of 
repose of powder blends.
Type
Fig. 2.1.1 b Response surface plots of the estimated effects of t and c on the angle of 
repose of powder blends.
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S iz *
Fig. 2.1.1 c Response surface plots o f the estimated effects o f s  and c on the angle o f 
repose o f powder blends.
As the concentration o f binder increases, so does the angle o f  repose. From the results, 
it is clear that in order to  produce a  directly compressible powder blend with good 
flow properties, either Encompress* o r camauba wax at a  low  concentration range, 
and mixed w ith ethyicellulose o f any size range tested in this analysis could and should 
be used. However, it should be noted that the angle o f repose o f the powder blends 
only becomes a problem when it is greater than 40°.
Therefore, if  we substitute the factor levels, -1 for the average particle size range, 1 for 
the type o f binder (camauba wax), and 40 for the maximum acceptable angle o f repose 
range into equation 2.1.4 above, and solve for c  (the %  concentration factor level), we 
can obtain the maximum amount o f camauba wax that could be added to  
ethyicellulose. Solving the equation gives a factor level value o f  4,417. This then 
translates to  a concentration o f ±  13%w/w camauba wax.
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Figures 2.1.2 a  - c are response surface plots o f the estimated effects o f the 
different response variables on the compressibility o f the powder blends. Only the type 
o f binder and concentration o f binder play a  statistically significant role in the resultant 
compressibility o f the directly compressible powder blends (Table 2.1.4). As with the 
flow (angle o f repose), it is the type o f binder which has the most notable influence on 
the compressibility o f the powder blend. (Fig. 2.1.2a and 2.1.2b). The response 
surfaces are moderately stable over the ranges o f type o f binder and average particle 
size range o f ethylcellulose.
2.1.3.2. Compressibility
Type
Fig. 2.1.2 a Response surface plots o f the estimated effects o f t and s  on the 
compressibility o f the powder blends.
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Fig. 2.1.2 b Response surface plots of the estimated effects of t and c on the 
compressibility of the powder blends.
Size
Fig. 2.1.2 c Response surface plots of the estimated effects of s and c on the 
compressibility of the powder blends.
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There is a very slight improvement o f the compressibility o f the powder blend as the 
average particle size range o f ethylcellulose increases. However, this does not warrant 
the separation o f the ethylcellulose into an ideal particle size range. As the 
concentration o f binder in the powder blends increase, so does the compressibility o f 
the powder blends increase exponential^ (Fig. 2.1,2c). This effect, however, is not as 
pronounced as that found with the type o f binder used. In developing a
regression model for the effect o f the independent variables on the compressibility o f 
the powder blends, only type o f binder (/) and concentration o f binder (c) main effects 
were significant (p < 0,05). Therefore, only these regression coefficients were included 
in the model. The rest o f  the coefficients were eliminated and the model was re- 
estimated by STATGRAPHICS.
Y „  (tc ) = 31,338 + 10,707t + 6,147c - equation2.1.5
where Ycom (t,c) is the estimated compressibility o f  the powder blends.
The squared multiple regression coefficient for this model was 0,62. This 
model shows that the type o f binder used has the principal effect on the compressibility 
o f the powder blends. Camauba wax has the best compactibility, which is then 
followed by EncompressR and cetyl alcohol. The concentration o f binder then produces 
the next most significant effect on compressibility. In order to produce a tablet with the 
best compressibility (as indicated from the slope o f the graph o f In compression force 
versus diametral crushing strength), it would be best to  use camauba wax at as high a 
concentration that is possible. This concentration however, will be limited by its 
adverse effect on the flow properties o f the blend.
In conclusion, the results show that to  produce a directly compressible powder 
blend (with the available ingredients) with good compressibility properties and minimal 
adverse effect on the flow o f the powder, the best choice would be camauba wax at a 
concentration o f approximately 10% - 15%w/w. Consequently, we will use low 
viscosity ethylcellulose together with 10%w/w camauba wax for the directly
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compressible powder blend was used in producing and further evaluating the cup 
portion of the core-in-cup tablets.
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2.2 PRODUCTION AND DEVELOPM ENT O F A ZERO-O RD ER RELEASE 
ORAL COM PRESSED TABLET
2.2.1 In troduction
In the previous analysis o f directly compressible powder blends, it was shown 
that low viscosity ethylcellulose mixed together with up to  13%w/w camauba wax was 
the most suitable combination for use as a directly compressible tabletting base for the 
cup portion o f the tablet. Therefore, ethylcellulose together with 10%w/w camauba wax 
(so as not to  adversely effect the flow o f the powder too much) was used as the 
directly compressible base for the cup portion o f the core-in-cup tablet. To produce a 
core tablet that would possibly release drug for a  period o f 8 o r more hours, it was 
decided that HPMC would be used, as it comes in various viscosity grades and has 
been used extensively in matrix sustained-release preparations (Wan et al., 1993; 
Kumar and Banker, 1993, M elia, 1991; Alderman, 1984). The low viscosity grade is 
useful in that it does not swell too  much in aqueous medium and erodes at a  constant 
rate. It can also be used in low concentrations.
This experiment describes a method that can possibly be automated to  
produce core-in-cup tablets that have the ability to  release soluble and insoluble drugs 
at a zero-order rate from an inert inactive cup. To check the validity o f the core-in-cup 
drug delivery system to  release both soluble and insoluble drugs at a zero-order rate, 
ibuprofen (insoluble) and caffeine (soluble) were used as model drugs. The experiment 
also investigates the release o f the model drugs from two different HPMC grades (low 
and intermediate viscosity grades) o f three different concentrations (5%, 10% and 
15%), as well as from core-in-cup and core-only tablets.
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The kinetics o f drug release from the core-in-cup tablets are examined as to 
how well the rate o f release fits the Korsmeyer eted. (1983b) relationship depicted in 
equation 2.2.1 or equation 2.2.2 below.
Me= k. t” - equation 2.2.1
M *
or,
log Me = log k +  n log t  - equation 2.2.2
M.
where M/M„ is the fractional release o f the drug, t  is the release time, k  is a 
constant incorporating structural and geometric characteristics o f the release device 
and n  is the time exponent indicative o f  the mechanism o f release. For example, n = 
0,5 for square root o f time kinetics and n = 1,0 for zero-order kinetics.
This classification has been successfully used by Ford et al. (1987) to  
characterize the release o f a number o f different drugs from HPMC matrices. I f  one 
plots the logarithm o f the fractional release versus the logarithm o f  time in minutes, the 
slope o f the graph will give one the value o f  the n  exponent. In order for equation
2.2.2 to  be applicable the intercept o f the graph must pass through the origin, i.e. log k  
must be zero. The correction method, however, is applicable to  the type o f  release o f 
drug from the tablets.
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This correction to  data can be achieved via correcting the sampling time data of;
(i) cumulative fractional release versus time, for a  zoo-order model,
(ii) cumulative fractional release versus the square root o f  time, for a  square root o f 
time model, o r
(iii) log o f  cumulative fractional release versus time, for a  first-order model.
The sampling times are then corrected by linear regression so that the graph passes 
through the origin (Ford et al. 1987). The intercept on the y-axis is calculated via 
linear regression and the times on the x-axis are adjusted depending on whether the 
intercept on the y-axis is above or below zero. In this way a  value is added or 
subtracted from the time values so that at time zero the graph goes through the origin.
2.2.2. M aterials and M ethods
2.2.2.1. Materials
HPMC K4M premium EP and HPMC K1SM premium EP were supplied by Colorcon 
Limited, England. HPMC K4M and K1SM have viscosities o f 3500 - 5600 cP and 
12000 - 21000 cP respectively as 2% solutions in water at 20°C. The polymers had 
already been screened through a No. 40 standard U S. sieve. Caffeine (E Merck, 
Darmstadt) and ibuprofen (Boots Co, S. A. Pty Ltd) were ground and the fraction 
passing through a No. 150 standard U.K. sieve was used. Ethylcellulose (Sigma 
Chemical Company, U S.A.) was used as supplied. All other reagents used were 
standard laboratory grade.
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2.22 .2 . Formulations
Flat disc-shaped tablets (cores) were made consisting o f 95%vv/w, 90%w/w and 
85%w/w o f caffeine (soluble model drug) or ibuprofen (insoluble model drug) in either 
HPMC K4M or HPMC K15M. Table 2.2.1 lists all the different formulations used in 
this study. The codes for the different formulations tested were obtained as follows:
(i) The first number from the left, i.e. 5 ,1 0  or IS is the concentration o f polymer 
used in the core tablet.
(ii) The second number from the left, separated from the first number by the letter 
H, i.e. H4 or H I S signifies HPMC K4M or HPMC K15M grades o f polymer used 
in the core tablet.
(iii) The second letter from the left, i.e. c or C signifies the core only (snail c) or 
core-in-oup (capital C) tablets.
(iii) The last letter from the left, i.e. C or I signifies the model drugs caffeine or 
ibuprofen respectively, used in the tablet.
Twenty grams o f each combination was prepared. The cores were compressed 
in a tabletting press to  a  thickness o f 2 mm and a diameter o f 7 mm, therefore the 
weights o f the cores varied slightly according to  the density o f the core mixture. Table
2.2.2 lists the average weights o f the cores together w ith their standard deviations. 
Cups were made o f 10%w/w camauba wax in ethylcellulose. The average weight o f the 
cups are also listed in table 2.2.2.
44
TABLE 2.2.1
Codes and descriptions o f different formulations tested
Code Formulation
Core
%w/w Polymer/Drug
Cup
10% Camauba wax/ 
Ethylcellulose
5H4CC 5% HPMC K4M/Caffeine Yes
10H4CC 10% HPMC K4M/Caffeine Yes
15H4CC 15% HPMC K4M/CafFeine Yes
5H15CC 5% HPMC K15M/Caffeine Yes
10H15CC 10% HPMC K15M/Caffeine Yes
15H15CC 15% HPMC K15M/Caffeine Yes
5H4cC 5% HPMC K4M/Caflfeine
10H4cC 10% HPMC K4M/Caffeine
15H4cC 15% HPMC K4M/Caffeine
5H15cC 5% HPMC K15M/Caffeine
10H15cC 10% HPMC K15M/CafFeine
15H15cC 15% HPMC K15M/Caffeine
5H4CI 5% HPMC K4M/Ibuprofen Yes
10H4CI 10% HPMC K4M/Ibuprofen Yes
15H4CI 15% HPMC K4M/Ibuprofen Yes
5H15CI 5% HPMC K15M/Ibuprofen Yes
10H15CI 10% HPMC K15M/Ibuprofen Yes
15H15CI 15% HPMC K15M/Ibuprofen Yes
5H4cI 5% HPMC K4M/Ibuprofen
10H4cI 10% HPMC K4M/Ibuprofen
15H4cI 15% HPMC K4M/Ibuprofen
5H15cI 5% HPMC K15M/Ibuprofen
10H15cI 10% HPMC K15M/Ibuprofen
15H15cI 15% HPMC K15M/Ibuprofen
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TABLE 2.2.2
Mean weights o f cores and cup used in the different formulations
Formulation Mean weight (mg) ± SD (n=20)
HPMC K4M/Caffeine
5H4cC 92,28 ± 2,66
10H4cC 88,27 ± 1,98
15H4cC 87,10 ±2,09
HPMC K15M/Caffeine
5H15cC 94,15 ±2,45
10H15cC 90,41 ± 1,86
15H15cC 88,27 ± 2,36
HPMC K4MZIbuprofen
5H4cI 91,10 ±2,62
10H4cI 90,92 ± 1,55
15H4cI 87,34 ± 3,52
HPMC K15M/Ibuprofen
5H15cI 85,42 ± 2,57
10H15cI 86,25 ± 1,06
15H15cI 85,22 ± 2,49
Ethylcellulose/Camauba wax
Cup 284,06 ±4,31
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22.2.3. Preparation o f compressed tablets
All powders for the cores were thoroughly mixed and granulated in an Erweka 
FGS granulator fitted with a S00 pm stainless steel screen. To form a coherent granule 
mass, 45%v/v alcohol in w ater was used as granulating agent. Once the granules were 
dry and passed through a  500 pm screen, they were compressed into cores on a 
M anesty F3 tabletting press using 7 mm diameter flat round punches. The press was 
set to compress the cores to  a thickness o f 2 mm. The hardness o f the cores were then 
measured on a Pharma Test PTB 311 hardness tester. The press was then adjusted to 
produce a tablet o f an approximate hardness o f approximately 40 N/m2. Table 2.2.3 
lists the hardness values o f the cores as well as the final core-in-cup tablets.
The ethylcellulose and the carnauba wax were thoroughly mixed and directly 
compressed into cups with a top punch which was sparkeroded, machined, and 
polished so that it produces a cup-shaped tablet o f 11 mm outer diameter, and an inner 
hollow core o f 7,5 mm diameter and 2 mm depth. The bottom  punch consisted o f a flat 
round 11 mm diameter punch. The press was set to  produce a tablet o f an approximate 
hardness o f 90 N/m2. Table 2.2.3 lists the hardness values o f the cups.
Once the cores and the cups were compressed, the cores were placed inside the 
cups and fed into the tabletting press to  finally be compressed into a single core-in-cup 
tablet. The cores and cups were then compressed between flat round punches o f 12 
mm diameter. The slightly larger punches and die cavity ensured that the core-in-cup 
tablet o f 11 mm diameter could easily be fed into the 12 mm die cavity. The press was 
then adjusted to  produce an approximate hardness o f 140 N/m2. Cores to  be tested and 
compared to  the core-in-cup tablets were also recompressed to  an approximate 
hardness o f 140N/m2 using flat 8 mm punches. This recompression o f the cores to be 
tested was necessary to  achieve the same relative hardness as the core portion o f the 
tablet in the core-in-cup compressed tablet.
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TABLE 2.2.3
Mean hardness o f cores, and core-in-cup used in the different 
formulations
Formulation Mean hardness (N/m2) ± SD (n=9)
Cores Core-in-cup
HPMC K4M/Cajfeine
5H4CC 44,61 ± 4,34 152,41 ±7,51
10H4CC 48,61 ± 6,53 158,70 ±4,36
15H4CC 40,70 ± 3,42 145,24 ± 5,58
HPMC K15M/Caffeine
5H15CC 38,32 ± 9,42 145,26 ±7,97
10H15CC 43,02 ± 3,86 150,25 ±5,19
15H15CC 41,42 ±4,80 147,55 ± 5,96
HPMC K4M/Ibuprofen
5H4CI 41,98 ±8,92 149,40 ±8,18
10H4CI 38,16 ±6,15 142,63 ± 7,75
15H4CI 42,94 ± 7,46 150,43 ±6,38
HPMC KI5M/Ibuprofen
5H15CI 44,30 ± 4,07 154,79 ±9,55
10H15CI 46,11 ±8,48 152,12 ±9,77
15H15CI 46,22 ±3.09 150,65 ±3,72
Cup
Ethylcellulose/Camaubcr wax
Cup 90,25 ±5,31 N/A
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Figure 1.6 graphically describes the various steps in the production process o f the 
core-in-cup compressed tablets.
The inactive cups and the active cores as well as the two being compressed 
together, can be accomplished automatically on a tabletting press that can be modified 
w ith feed shoes that feed the cores into the cups and th a t feed these into a die cavity to  
be compressed together. It is also a  very simple method using exceedingly few 
adjuvants, and is applicable to  a wide variety o f drugs. Figure 1.6 graphically describes 
the compression o f  the core-in-cup tablets and the dimensions o f the punches and dies 
used to  produce these compressed tablets.
2.2.2.4 Release Studies
The B.P. 1988 paddle method was utilised in all the release studies. A volume 
o f 500 ml o f deionized water, equilibrated at 37°C ±  0,5 °C, was used as the release 
medium. All experiments were carried out at 50 rpm. The release rates o f the tablets 
were monitored using a 6 beaker Caleva model 7ST dissolution tester. At appropriate 
time intervals 2,0 ml samples were withdrawn for analysis. For the release o f caffeine 
from the tablets, the samples were analyzed spectrophotometrically at a wavelength o f 
242 nm using a Beckman DU 650 spectrophotometer. Linearity was established for 
aqueous solutions o f caffeine in the range o f 6,25 - 200 |ig/ml. For the release o f 
ibuprofen from the tablets, 2 ml methanol was added to  the sample withdrawn, mixed 
well on a vortex mixer, and measured at a wavelength o f 216 nm. Linearity was 
established for a 50%v/v methanol in deionized w ater ibuprofen solutions in the range 
o f6,25 - 200 pg/ml. The release profiles o f a minimum o f 3 tablets from each o f 3 
different batches (n = 9) were analyzed. The rate o f release o f caffeine and ibuprofen 
from cores only were also analyzed.
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2.2.2.5 Calculation o f time exponents
The release rate exponents o f drug release from the core-in-cup tablets were 
examined as to how well the rate o f release fits the Korsmeyer et al. (1983b) 
relationship depicted in equation 2.2.2. Plots o f the logarithm o f the fractional release 
versus the logarithm o f time in minutes were plotted for each formulation. The time 
exponent was then calculated from the slope o f the plot via linear regression. In order 
for equation 2.2.2 to be applicable, the intercept o f the graph must pass through the 
origin, i.e. log k  must be zero. This correction to data was achieved via correcting the 
sampling time data o f cumulative fractional release versus the square root o f tune for 
the core only tablets, and via correcting time data o f cumulative fractional release 
versus time for the core-in-cup tablets. The sampling times were then corrected by 
means o f linear regression so that the graph passed through the origin, as per Ford et 
al. (1987). In order to  determine whether the drug was released mainly via zero-order 
or square root o f time kinetics, the plot with the best correlation coefficient was used. 
Only the linear portions o f the graphs were used to  calculate the time exponents. The 
mean release rates o f  the core-in-cup tablets were calculated via linear regression o f 
the linear portion o f  the plot o f cumulative fractional release versus time.
2.2.3 R esults and Discussion
Table 2.2.4 lists the calculated time exponents as calculated from the results 
using equation 2.2.2 as well as the average release rates using equation 2.2.1 for the 
zero-order core-in-cup systems. Figures 2.2.2 and 2.2.3 show the release rate o f 
caffeine from the core-in-cup tablets when HPMC K4M and HPMC K15M were used 
in the core, as well as the release from the cores without the cup coatings. These 
results indicate that the rate o f release o f caffeine (a soluble drug) is released from the 
core-in-cup tablets at a near zero-order rate o f release for 80% o f the release time. 
This occurred no m atter which concentration o f HPMC K4M was used. This near 
zero-order rate o f release is confirmed for the release o f caffeine from the HPMC 
matrix core-in-cups from equation 2.2.2.
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TABLE 2.2.4
Mean time exponents and release rates from  core only matrices and core-in-cup 
tablets used in the different formulations
Formulation Exponent n 
value ± SD (n=9)
Mean release rate 
(mg/min.) ± SD (n=9)
HPMC K4M/Caffeine
5H4CC 0,973 ± 0,046 0,174 ±0,036
5H4cC 0,562 ± 0,041
10H4CC 0,988 ± 0,089 0,115 ±0,042
10H4cC 0,594 ± 0,033
15H4CC 0,987 ± 0,057 0,105 ±0,033
15H4cC 0,617 ±0,023
HPMC K15M/Caffeine
5H15CC 1,026 ±0,096 0,115 ±0,045
5H15cC 0,534 ±0,031
10H15CC 1,056 ±0,013 0,106 ±0,035
10H15cC 0,516 ±0,098
15H15CC 1,058 ± 0,082 0,081 ±0,048
15H15cC 0,477 ± 0,069
HPMC K4M/lbuprofen
5H4CI 0,997 ± 0,032 0,126 ±0,025
5H4cI 0,496 ±0,031
10H4CI 0,984 ± 0,039 0,094 ± 0,035
10H4cI 0,451 ±0,099
15H4CI 0,979 ±0,019 0,081 ±0,020
15H4cI 0,409 ± 0,026
HPMC K15M/Ibuprofen
5H15CI 0,987 ± 0,062 0,091 ± 0,024
5H15cI 0,540 ±0,061
10H15CI 1,015 ±0,050 0,078 ±0,016
10H15cI 0,553 ± 0,069
15H15CI 1,041 ± 0,021 0,055 ± 0,042
15H15cI 0,499 ±0,031
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f ig . 2.2.2 Caffeine release rates from HPMC K4M drug delivery systems.
__Core-in-cup tablets. _ . .  Core only tablets.
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When HPMC K15M is used as the matrix polymer there is a slight negative 
deviation in the rate o f release (i.e. the rate decreases slightly with time) which results 
in an exponent n  o f  greater than 1. For these systems, the larger than 1 the exponent n 
is, the less closer it is to  zero-order release, just as it does for a fraction less than 1 for 
a positive deviation. Deviation o f the time exponent n  away from 1 occurs more with 
core-in-cup tablets containing HPMC K15M than with HPMC K4M. This is because 
there is more swelling o f the HPMC K15M in the release medium. The higher the 
concentration o f HPMC K4M or HPMC K15M polymer in the core, the lower the rate 
o f release and the longer the time o f near zero-order release. The unique high rate o f 
release initially is due to  the occurrence o f an immediate release o f drug from the 
surface o f the polymer matrix core as it comes into contact with the release medium. 
During manufacture some o f the drug particles are exposed at the surface o f the matrix 
and not trapped within. Also, the HPMC swells out very slightly as it comes into 
contact with the aqueous solution, even though its concentration in the core is low. 
This allows an immediate release o f drug via diffusion in the initial period o f  release as 
well as a larger initial surface area exposed to  the release medium. Consequently, after 
approximately 60 minutes this swelling above the circumference walls o f  the cup is 
eroded to  a flat constant surface area. The HPMC K15M swells more than the HPMC 
K4M, therefore more caffeine is released via diffusion control for the HPMC K15M 
tablets than the HPMC K4M tablets. The release o f caffeine from the tablets however, 
settles down to  a  near zero-order rate o f release after 3 0 -6 0  minutes. This is due to  
the fact that the release o f  caffeine from the polymer matrix is mainly due to  erosion o f 
the polymer and constant diffusion through the slightly swollen polymer surface.
The rates o f release o f ibuprofen from HPMC K4M and HPMC K15M core-in­
cups and cores only are shown in figures 2.2.4 and 2.2.5. The results are very similar 
to  that o f caffeine, except that the rate o f  release over the linear period for both 
polymers are closer to  zero-order than that for caffeine. The time exponents n vary 
from 1,041 to  0,997.
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10H4CI - a -  10H4ol
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Fig. 2 .2 .4  Ibuprofen release rates from HPMC K4M drug delivery systems.
__ Core-in-cup tablets. _  .. Core only tablets
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Fig. 2 .2 .5  Ibuprofen release rates from HPMC K15M drug delivery systems.
__ Core-in-cup tablets. _  .. Core only tablets
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This is well in line with predicted theory in that the release o f ibuprofen from the 
polymer matrix is predominantly through erosion o f the polymer surface. The reason 
for this, is that ibuprofen is not very soluble in aqueous solution and negligible drug is 
released via diffusion from the polymer matrix.
Again, like the release o f  caffeine from the core-in-cup tablets, the release o f 
ibuprofen from the HPMC K4M tablets is closer to  perfect zero-order than the release 
o f ibuprofen from the HPMC K15M  tablets. The difference, however, for all practical 
purposes is less than the difference for the caffeine core-in-cup tablets.
In comparing all the core-in-cup tablet formulations with the core-only 
formulations, one can see that there is a  significant difference in the release exponents 
o f both the aqueous soluble caffeine (p = 0,0000077) and insoluble ibuprofen (p -  
0,0000023). The calculated probabilities were based on the difference o f the release 
exponents for the core only and core-in-cup tablets, and treated as a single sample test, 
since they were both tested in the same release fluid. The core-only formulations 
release drug at a rate equivalent to square root o f time kinetics. This can ue explained 
by the fact that as the core tablet erodes the surface area o f the tablet decreases with 
time and hence less drug is released with time. Therefore, from an in vitro release point 
o f view, the core-in-cup formulation is a superior formulation to the traditional matrix 
type o f compressed tablet.
It is possible, through the manipulation o f the grade o f HPMC polymer used 
(or any other hydrophillic polymer or mixture o f polymers that erodes constantly with 
time), the quantity o f HPMC polymer used, and the exposed surface area o f the core 
o f the HPMC polymer matrix, to  produce a core-in-cup compressed tablet that can 
release a constant amount o f drug over a predetermined period o f time. In this study, 
the time o f constant release varied from approximately 8 hours for the 5%w/w caffeine 
in HPMC K4M core-in-cup tablets, to approximately 23 hours for the 15%w/w 
ibuprofen in HPMC K15M core-in-cup tablets. Therefore, it is possible to produce a 
zero-order compressed tablet that only needs to  be dosed once or twice daily
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depending on were the drug is absorbed in the gastrointestinal tract and its residence 
time. With the present advancement o f robotics and automated technology it will be 
reasonably easy and inexpensive to fully automate the manufacture o f this core-in-cup 
compressed tablet. Each set o f punches, however, will be specific for each core-in-cup 
tablet, as it is the diameter and depth o f  the cup indentation that determine the amount 
o f drug and polymer to  be included in the tablets.
To solve the problem o f only being able to  produce a  core-in-cup tablet that 
can only accommodate a specific mass o f active core, a  new adjustable punch that can 
produce cup tablets o f  different depths will be developed and evaluated in the next 
section. The ability to  adjust the thickness o f the core tablet will add flexibility to  the 
dosage form, and also allow it to  be adjusted to  oblige powder o r granule mixes that 
vary in their compressed density and hardness. This flexibility is critical for effective 
tablet manufacture.
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2.3 CO M PRESSION PR O PERTIES O F CONTROLLED RELEASE CORE-IN­
CUP COM PRESSED TABLETS FRO M  A NEW  ADJUSTABLE PUNCH.
2.3.1 In troduction
In order to  be able to  produce cup tablets that have the ability to  be adjusted 
for various core tablet thicknesses (which change in thickness according to  the 
adjuvants used as well as the amounts o f drug and adjuvants used) the new novel 
punch discussed in section 1.5 was designed and used in this study. By adjusting the 
protrusion distance o f the inner central bolt, the depth o f the resultant cup tablets can 
be adjusted to  accommodate cores o f different hardness and mass.
The purpose o f this study, was to  test the resultant effectiveness o f the cup 
tablets produced by this new adjustable punch in producing cups o f  various depths for 
core-in-cup tablets, as well as to  test whether a typical core o f ibuprofen as the model 
drug with HPMC K4M, has any effect on the cup portion o f the core-in-cup tablets 
produced from the punch. A friability test was also conducted on the ibuprofen in 
HPMC K4M core-in-cup tablets to  check the intactness o f the core to  the cup. Finally, 
to  check the consistency o f the erosion o f the core and the release from the deeper 
cores produced by the new punch, a release rate analysis over a period o f 8 hours was 
conducted.
As the depth o f the cup tablet is increased, it becomes more and more fragile 
and there is a limit to  its depth. A measure o f the ability o f a tablet to  withstand impact, 
as would be required in the production o f the core-in-cup tablets, is its friability. The 
main factors that impact on the friability o f these ethylcellulose and camauba wax cup 
tablets include, the depth o f the cup, the amount o f binder in the cup, and its hardness. 
Since HPMC swells when it comes into contact with an aqueous environment, it could 
swell to such an extent that it could cause the cup to be split. Accordingly, the 
different cup formulations were tested for their ability to resist splitting in aqueous
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dissolution medium or not. Therefore, it was decided to  examine these three factors at 
three different levels to ascertain their effect on the friability and splitting open o f the 
cup tablets. This study then results in a 33 factorial design. The dependencies were 
statistically analysed using analysis o f variance and multiple regression analyses.
2.3.2 M aterials and M ethods
2.3.2.1 Materials
HPMC K4M premium EP was supplied by Colorcon Limited, England. HPMC K4M 
has a viscosity o f 3500 - 5600 cP as a 2% solutions in w ater at 20°C. The HPMC had 
already been screened through a No. 40 standard U S. sieve. Ibuprofen (Boots Co,
S.A. Pty Ltd) was ground and the fraction passing through a No. 150 standard U.K. 
sieve was used.
Ethylcellulose and Camauba wax (Sigma Chemical Company, U.S.A.) were used as 
supplied. All other reagents used were standard laboratory grade.
2.3.2.2 Study design
The study followed a 33 factorial experimental design. The amount o f camauba 
wax in the cup (c), hardness o f the cup (h) and cup indent depth (d) wore used as 
independent variables. The normalized factor levels o f the independent variables are 
presented in table 2.3.1. In the 23 factorial points, the cup tablets were made in 
duplicate batches, and in the centre point, in quadruplicate batches. Therefore, the total 
number o f  runs was 38. Friability o f  the cup tablet and splitting o f the cup in the final 
core-in-cup tablet w ere the dependant variables. This design has also been used with 
success by M erkku et al. (1994) to  determine the influence o f  granulation and 
compression process variables on the flow rate o f granules and on tablet properties.
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TABLE 2.3.1
Levels o f independent variables.
Variable Factor level Units
-1 0 1
Amount o f camauba wax in cup (c) 5 10 15 %W/w
Hardness o f compressed cup (h) 50 75 100 N/m2
Depth o f the cup (d) 2 4 6 mm
2.3.2.3. Formulations
Cup tablets o f various depths and amounts o f camauba wax in ethylcellulose 
were compressed in a  M anesty F3 tabletting press. The hardness o f  the cup tablets 
were then measured on a  Pharma Test PTB 311 hardness tester. The press was then 
adjusted to  produce cup tablets o f approximate hardness o f 50 N/m2, 75 N/m2, and 100 
N/m2. The ethylcellulose and the camauba wax were thoroughly mixed and directly 
compressed into cup tablets by means o f  adjusting the protrusion o f the inner bolt o f 
the adjustable punch to  the various depths tested so that it produces a  cup-shaped 
tablet o f 11 mm outer diameter, and an inner hollow core o f 7,5 mm diameter. The 
bottom  punch consisted o f  a flat round 11 mm diameter punch.
Production o f core-in-cup tablets for release rate analysis, containing 5%w/w 
HPMC K4M  in ibuprofen as the core, 4 mm final cup depth, containing 15% camauba 
wax in ethylcellulose as the cup, and compressed to  a  cup hardness o f approximately 
100 N/m2 and final core-in-cup hardness o f approximately 140 N/m2, were produced as 
described previously in section 2.2.2 3.
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23 .2 .4  Measurement o f Friability
The friability o f the cup tablets and the final core-in-cup tablets were measured 
on a Roche Friabilator (Hoffinan la Roche, Basel). After weighing, 10 cup tablets from 
each run were rotated for 20 minutes and then re-weighed to  test for % loss o f weight.
2.3.2.5 Measurement o f  cup splitting
The core-in-cup tablets were made by compressing the different cup tablets 
together w ith cores containing 15%w/w HPMC K4M in ibuprofen. Core tablets o f 
approximately 100 N/m2 o f 2 mm, 4 mm and 6 mm thickness to  match the depth o f the 
cup tablets were produced. Core-in-cup tablets were then compressed to  l mm, 3 mm 
and 4 mm for the 2 mm, 4 mm and 6 mm cup tablets respectively, to  be tested for 
splitting. The core-in-cup tablets were placed in the dissolution apparatus as described 
above, and physically inspected for any splitting o f  the cup after 60 minutes. I f  any 
splitting o f the cup tablets occurred it would occur before 60 minutes after being 
immersed in distilled w ater at 37°C and agitated at SO rpm. The cup tablets were 
qualitatively adjudged to  be split or not split.
2.3.2.6 Release Studies
The B.P. 1988 paddle method was utilised in all the release studies. A volume 
o f 1000 ml o f  deionized water, equilibrated at 37°C ± 0,5 °C, was used as the release 
medium. All experiments were carried out at 50 rpm. The release rates o f the tablets 
were monitored using a 6 beaker Caleva model 7ST dissolution tester. At appropriate 
time intervals 2,0 ml samples were withdrawn for analysis, 2 ml methanol was added, 
mixed on a vortex mixer, and analyzed spectrophotometrically at a wavelength o f 216 
nm using a Beckman DU 650 spectrophotometer. Linearity was established for 50%v/v 
methanol in deionized w ater ibuprofen solutions in the range o f 6,25 - 200 pg/ml. The 
release profiles o f 3 tablets from  each o f 3 different batches (n = 9) were analyzed.
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2.3.2.7 Statistical analysis
Analysis o f variance was performed on the data presented in Table 2.3.3 using 
STATGRAPHICS v 5 (Statistical Graphics Corporation, U.S.A.). The independent 
variables were %  camauba wax in the cup tablet, depth o f the cup tablet, and hardness 
o f the cup tablet, while the dependent variables were friability o f the cup tablet and 
splitting o f the cup tablet in aqueous medium. Response-surface plots were 
constructed for the above variables, in order to  determine the optimal combination o f 
the variables. M ain effects and significant interactions were also calculated. Simple 
regression models for the three independent variables were also developed from the 
results as follows;
Y1 (c,h,d) = a0 + a,c + a ji  + a / i  + a /:h  + a f d  + a jid  + + a ji2 + a<ff
al(phd  - equation 2.3.1
where a0,...,a to are the coefficients o f the system, c, h  and d  denote the %  camauba 
wax in the cup tablet, hardness o f the cup tablet and depth o f the cup tablet, 
respectively.
Each term in the final regression equation for the friability or the splitting was 
only included if the f-test p  value was less than 0,05. The regression coefficients for 
those effects that were considered insignificant were eliminated and the model was re- 
estimated.
2.3.3 R esults and Discussion
Table 2.3.2 lists the hardness values, the friability and the splitting results o f the 
cup tablets for the different runs tested in the study. Table 2.3.3 lists the relevant 
statistical parameters calculated from the results o f this study for the effect o f the three 
independent variables on the friability and splitting o f the cup tablets analyzed. All 
statistical analysis was carried out on all the runs (total 38).
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TABLE 2.3.2
Friability and Splitting o f cup tablets (c, % camauba wax; h, hardness; d, depth o f 
cup). Subscripts abcd designate replicates.
Run c h d Mean hardness 
(N/m2)
± SD (n=3)
Friability Splitting
la -1 -1 -1 53,17 ±3,71 0,19 -1
lb -1 -1 -1 45,99 ± 3,79 0,51 -1
2 -1 -1 0 51,84 ± 1,67 1,06 1
3a -1 -1 1 63,07 ± 5,06 3,32 1
3b -1 -1 1 52,82 ± 4,92 2,80 1
4 -1 0 -1 72,97 ± 2,89 0,14 -1
5 -1 0 0 78,37 ± 3,72 0,48 1
6 -1 0 1 74,15 ±6,55 1,32 1
7a -1 1 -1 98,16 ±5,32 0,00 -1
7b -1 1 -1 106,39 ± 6,66 0,21 -1
8 -1 1 0 98,81 ± 7,43 0,18 1
9a -1 1 1 92,53 ± 3,73 0,67 1
9b -1 1 1 99,16 ±6,06 0,41 1
10 0 -1 -1 56,91 ±5,13 0,13 -1
11 0 -1 0 54,58 ± 5,85 0,40 1
12 0 -1 1 50,57 ± 7,03 1,13 1
13 0 0 -1 71,03 ± 7,36 0,07 -1
14. 0 0 0 72,06 ± 3,43 0,44 1
14b 0 0 0 78,15 ±6,24 0,09 1
14. 0 0 0 75,76 ± 8,47 0,26 1
14, 0 0 0 70,19 ±4,85 0,31 1
15 0 0 1 75,07 ± 2,88 0,64 1
16 0 1 -1 98,11 ±6,71 0,03 -1
17 0 1 0 101,65 ±7,83 0,06 -1
18 0 1 1 96,92 ± 8,00 0,28 -1
19a 1 -1 -1 48,90 ± 5,89 0,04 -1
19b 1 -1 -1 50,67 ± 7,27 0,04 -1
20 1 -1 0 56,76 ±4,16 0,31 1
21a 1 -1 1 48,75 ± 4,20 0,47 1
21b 1 -1 1 55,74 ± 5,85 0,77 1
22 1 0 -1 74,99 ± 8,34 0,01 -1
23 1 0 0 69,30 ± 2,80 0,12 -1
24 1 0 1 78,49 ± 6,22 1,32 1
25a 1 1 -1 96,24 ±6,91 0,00 -1
25b 1 1 -1 97,79 ± 9,37 0,00 -1
26 1 1 0 102,13 ± 5,56 0,00 -1
27a 1 1 1 95,53 ± 7,96 0,01 1
27b 1 1 1 103,55 ± 3,68 0,05 -1
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TABLE 2.3.3
Relevant statistical parameters
Source
effect
Estimated effects 
±  standard error 
(28 d .f)
/rv a lu e Regression
coefficients
Regression
coefficients
re-estimated
Friability
average 0,202 ± 0.096
constant 1,375 -0,271
c -0 J1 3  ±0,101 <0,0001 -0,198 -0,095
h -0,713 ±0,101 <0,0001 -0,029 -0,008
d 0,823 ± 0,101 <0,0001 0,689 0,989
ch 0,483 ±0,115 <0,0005 0,002 0,002
cd -0,606 ±0,115 <0,0001 -0,030 -0,030
hd -0,640 ±0,115 <0,0001 -0,006 -0,006
cc 0,257 ±0 ,192 0,1908 0,005
hh 0,174 ±0 ,192 0,3824 0,000
dd 0,300 ±0 ,192 0,1284 0,037
Splitting
average 0,600 ±0.217
constant -7,041 -2,885
c -0,462 ± 0,229 0,0543 0,061
h -0,615 ±0,229 0,0122 0,084 -0,012
d 1,692 ±0,229 < 0,0001 2,023 1,731
ch -0,400 ±0,262 0,1380 -0,002
cd -0,200 ± 0,262 0,4596 -0,010
hd -0,400 ± 0,262 0,1380 -0,004
cc 0,133 ± 0,434 0,7644 0,003
hh -0,533 ± 0,434 0,2297 -0,000
dd -1,200 ±0,434 0,0100 -0,150 -0,163
2.3.3.1 Friability
Figures 2.3. la  - c are response surface plots o f the estimated effects o f the % 
camauba wax, hardness and depth o f cup tablet on the friability o f the tablet cups. The 
plots have been drawn on the basis o f the model by assigning a constant value to one 
o f the variables. All three variables play a significant role in the resultant friability o f
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the cup tablets. Depth o f the cup tablet has the most significant influence on its 
friability (Fig. 2.3.1a and 2.3. lb).This is particularly pronounced at lower levels o f 
camauba wax (Fig. 2.3. la).
As the % camauba wax increases in the formulations, the cup tablets have an 
increased ability to  withstand the increase in friability as the depth o f the cup increases. 
There is a similar ability o f the cup tablet to withstand increased friability with an 
increase in depth, as the hardness o f the tablet is increased (Fig. 2.3. lb). This similarity 
in effect on the friability is evidenced from the estimated main effects o f -0,713 for 
both c and h  as well as the interaction effects o f -0,606 and -0,640 for cd  and hd  
respectively.
Fig. 2.3.1 a Response surface plots of the estimated effects o f c and don  the friability
of the tablet cups.
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As the % o f camauba wax in the cup tablets increases, the friability o f the cup 
tablets decreases (Fig. 2.3. lc). Since the camauba wax acts as a binder for the 
ethylcellulose this effect is expected. This binding efficiency is at its maximum when 
the compression force is increased, and the difference in the friability at the higher 
compression force (equivalent to  a hardness o f ±  100 N/m2) is less pronounced than 
that at the lower compression force (equivalent to  a hardness o f ± 50 N/m2).
In developing a regression model for the effect o f the independent variables on 
the friability dependent variable, the main effects as well as the second order 
interaction effects were significant (p < 0,05). Therefore, the regression coefficients for 
these effects were included in the model. The rest o f the coefficients were eliminated 
and the model was re-estimated by STATGRAPHICS.
Yf (c,h,d) -  -0,271 - 0,095c - 0,008h + 0,989d + 0,002ch - 0,030cd-0,006hd-
equation 2.3.2
where Yf  (c,h,d) is the estimated friability o f the cup tablets.
The squared multiple regression coefficient for this model was 0,902. This model 
shows that depth o f  the cup tablet has the major adverse effect on the friability o f the 
cup tablet. As the depth increases the friability increases. The %  camauba wax then 
produces the next m ost significant effect on the friability. Camauba wax and hardness 
o f the cup tablet both decrease the friability o f  the cup tablet. Clearly, in order to  
produce a cup tablet w ith minimal friability, the compression force (tablet hardness) 
and %  camauba wax m ust be maximised, while the depth o f  the cup should be 
minimised. However, it should be noted that the friability o f the cup only really 
becomes a problem when the % loss after 20 minutes in the fiiabilator becomes larger 
than 4%. None o f the formulations in this study exceeded this value.
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2.3.3.2 Splitting
Figures 2.3.2a - c are response surface plots o f the estimated effects o f the % 
camauba wax, hardness and depth o f cup tablet cup on the splitting o f the cups in the 
core-in-cup tablets placed in an aqueous dissolution medium. Those tablets that split in 
aqueous dissolution medium were assigned a value o f -1,0 and those that remained 
intact (not split) were assigned a value o f  1,0. Only the hardness and depth o f the cup 
tablets play a significant part in the resultant splitting o f the cup tablets. As with the 
friability, depth o f the cup tablet has the most significant influence on its splitting in 
aqueous solution. (Fig. 2.3.2a and 2.3.2b). The response - surfaces are reasonably 
stable over the ranges o f hardness and % camauba wax. There is a  very slight decrease 
in the tendency to  split as the % camauba wax increases from 5% to 10%. However, 
as the % camauba wax increases from 10% to  15% there is a slight tendency for the 
cup tablets to split at low hardness. This is made evident from the significant dd  
interaction. As the hardness o f the cup tablet increases, there is a modest decrease in 
the tendency to split which is more pronounced at increased depths. The ability to  split 
in aqueous medium however, decreases in a linear fashion as the hardness o f the cup is 
increased (Fig. 2.3.2c).
In developing a regression model for the effect o f the independent variables on 
the splitting in aqueous medium dependent variable, only depth and hardness main 
effects as well as the second order dd  interaction effect were significant (p < 0,05). 
Only these regression coefficients were therefore, included in the model. The rest o f 
the coefficients were eliminated and the model was re-estimated by STATGRAPHICS.
Yf (h,d) = -2,885 - 0,012h + 1,731d-0,163dd  - equation 2.3.3
where Yf (h,d) is the estimated friability o f the cup tablets.
The squared multiple regression coefficient for this model was 0,754.
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Fig. 2 .3 .2  a  Response surface plots of the estimated effects o f the c and d  on the 
splitting o f the cups in the core-in-cup tablets placed in an aqueous dissolution 
medium.
F ig. 2 .3 .2  b  Response surface plots o f the estimated effects of the h and d  on the 
splitting o f the cups in the core-in-cup tablets placed in an aqueous dissolution 
medium.
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Fig. 2 .3 .2  c  Response surface plots o f the estimated effects o f the c and h on die 
splitting of the cups in the core-in-cup tablets placed in an aqueous dissolution 
medium.
This model shows that the depth o f the cup tablet has the principal adverse effect 
on the splitting o f the tablet. As the depth increases the splitting in aqueous 
dissolution medium increases. The hardness erf the cup tablet produces the next 
most significant effect on the friability. This effect however, is much less 
significant as compared to the depth o f the cup tablet. It does however, decrease 
the ability o f the cup tablet to  split in aqueous medium. In general, splitting o f the 
cup tablets at depths o f 6 mm is a  problem  and will have to be investigated 
further. The problem  o f the splitting lies w ith the swelling o f the HPMC polymer 
in aqueous solution.
2 .3 .3 .3  Release rate
To check that the new core-in-cup tablet produced by the adjustable punch
still has the ability to release drugs at a zero-order rate of release without splitting,
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a core-in-cup tablet with the optimal parameters was manufactured and tested. The 
results above indicate that a cup tablet containing 5%w/w HPMC K4M, compressed to 
a depth o f 4 mm and containing 15%w/w camauba wax in ethylcellulose as the cup, and 
compressed to  a hardness o f 100 N/m2 and final core-in-cup hardness o f 160 N/m2, is 
best from a friability and lack o f splitting point o f view. Therefore, a tablet o f these 
dimensions and processing parameters was manufactured and tested. Figure 2.3.3 plots 
the rate o f release o f ibuprofen from core-in-cup tablets.
The core-in-cup system releases the ibuprofen at a near zero-order rate o f 
0,156 mg/min. This rate was calculated from the slope o f the plot o f cumulative 
concentration versus time from 60 minutes to 720 minutes. The correlation coefficient 
for this plot was 0,999.
Time (minutes)
Fig. 2.3.3. Ibuprofen release rates from core-in-cup tablets.
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To check whether the rate o f release was zero-order, or according to the 
'square root o f time’, plots o f log o f cumulative concentration versus time, and 
cumulative concentration versus square root o f time, were plotted respectively. The 
correlation coefficients for these were 0,983 and 0,921 respectively. Therefore, a  zero- 
order rate o f release best describes the release rate from the ibuprofen core-in-cup 
system. Extrapolating the zero-order rate o f release o f 0,156 mg/min. the core-in-cup 
system can release drug for up to  18 hours. This is too long for an average oral system 
as gastrointestinal transit time is not much longer than 8 -1 2  hours on average. 
Polymers that erode at a  quicker rate need to  be investigated, to  design a  system that 
releases drugs from the core-in-cup system at a zero-order rate for a  shorter time. It 
would be desirable if  the polymer used in the core o f  the tablet did not swell, but 
eroded at a controlled rate from the core-in-cup tablet. Therefore, in the next section 
the use o f nonswellable polymers as sustained-release binders in the core o f  the tablets 
will be investigated.
2.3.3.4 Friability o f core-in-cup
The friability test was conducted on the final core-in-cup tablet mentioned in 
section 2.3.3.3 above. After 20 minutes in the fiiabilator the percentage weight loss 
from the core-in-cup tablets was 1,5 ± 0,437 in  = 3). None o f the core tablets were 
dislodged from the core-in-cup tablets during the test. Therefore, the core-in-cup 
tablets do maintain their intactness during the test. They therefore, should be able to 
keep intact throughout their movement in the gastrointestinal tract which will be tested 
in Beagle dogs later.
73
2 4 TH E EFFEC T O F PRO CESSIN G  VARIABLES ON TH E RELEASE OF 
IBVPROFEN AND CAFFEINE FRO M  CONTROLLED RELEASE 
NONSW ELLABLE CO RE-IN -CU P COM PRESSED TABLETS.
2.4.1 In troduction
In the previous experiment it was ascertained that the core-in-cup tablets have 
the ability to  release soluble and insoluble drugs at a zero-order rate from an inactive 
cup. It was found that it is possible, through the manipulation of, (i) the grade o f 
HPMC used (or any other hydrophillic polymer or mixture o f polymers that erodes 
constantly with time), (ii) the quantity o f HPMC polymer used, and (iii) the exposed 
surface area o f the core o f the HPMC polymer matrix, to  produce a core-in-cup 
compressed tablet that can release a constant amount o f drug over a predetermined 
period o f time. Unfortunately, as the depth o f the cup portion o f  the core-in-cup 
compressed tablet increases to  6 mm or more, some o f  the cups began to  split in 
aqueous medium. This is because the efficiency o f  the binder in the cup portion o f the 
tablet was not enough to  overcome the swelling o f the HPMC polymer when it comes 
into contact with aqueous medium. As the viscosity grade and concentration o f the 
polymer used increases so does the swelling o f the polymer increase (Wan et al., 1993) 
especially in the vertical direction (Colombo et al.y 1990).
The purpose o f these experiments thurifers to  test the effectiveness o f 
nonswellable polymers in producing the core o f a core-in-cup tablet that does not swell 
to  any appreciable extent when it comes into contact with aqueous dissolution fluid. 
The advantage o f such a polymer would be that it would not split the cups open, and it 
would release the drug from a constantly eroding surface or constant difiusional area 
and path. It must however, be capable o f releasing drugs over a period o f at least 8 
hours at a constant rate.
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Accordingly, it was decided to  first test the rate o f release o f a soluble drug 
(caffeine) and insoluble drug (ibuprofen) from polyethylene glycol 6000 (PEG 6000), 
acacia gum, tragacanth and hydroxyethylcellulose (HEC) from core-in-cup tablets. 
Secondly, it was decided to examine the processing variables o f concentration o f 
polymer (c) and hardness o f tablet core (h), on the maximum time o f constant release 
(tmax) o f caffeine and ibuprofen from the most suitable polymers. The rate o f  release o f 
caffeine was tested in 0,1 M HC1 aqueous dissolution fluid. The rate o f release o f 
ibuprofen was tested in 0,2 M phosphate buffer at a pH o f 7,2. This study then results 
in a 32 factorial design. The dependencies were explained using analysis o f variance 
and multiple regression analysis.
2.4.2 M aterials and M ethods
2.4.2.1 Materials
Acacia, PEG 6000 and tragacanth gum were supplied by Saarchem (Pty) Ltd, 
South Africa. The acacia, PEG 6000 and tragacanth gum had viscosities o f S3 cps, 43 
cps, and 12S0 cps, respectively, as 4% aqueous solutions at 23 °C. HEC was supplied 
by Riedel de-Haen, South Africa and had a viscosity o f 2100 cps as a  4% aqueous 
solution at 23 °C. Ibuprofen (Boots Co, S .A  Pty Ltd) and caffeine (Sigma Chemical 
Company, U S A ) was ground and the fraction passing through a No. 150 standard 
U.K. sieve was used. Ethylcellulose (Sigma Chemical Company, U.S.A.) and camauba 
wax (Sigma Chemical Company, U.S.A.) were used as supplied. All other reagents 
used were standard laboratory grade.
2.4.2.2 Study design
The study followed a sequential 21 preliminary study followed by a 32 factorial 
experimental design. In the preliminary experimental phase, the caffeine and ibuprofen 
were formulated in each polymer at tw o different concentrations in order to  assess 
which polymer gave a  constant release time closest to  a maximum o f 8 - 12 hours.
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Once the most suitable polymer was found, a 32 factorial design study was conducted 
for each o f ibuprofen and caffeine. The amount o f polymer in the core (c) and hardness 
o f the core (h) were used as independent variables. The normalized factor levels o f the 
independent variables are presented in table 2.4.1. All the outside factorial points o f the 
core tablets were made in duplicate batches, and in quadruplicate batches in the centre 
point. Therefore, the total number o f runs was 20 for each drug. The maximum time o f 
constant release (including the initial higher release rate) o f drug from the core-in-cup 
in the relevant dissolution fluid was the dependant variable.
TABLE 2.4.1
Levels o f independent variables.
Variable Factor level Units
-1 0 1
Concentration o f polymer in core (c) 5 10 15 % W/w
Hardness o f compressed core (h) 40 50 60 N/m2
2.4.2.3. Formulations
For the preliminary study on the suitability o f the polymers to caffeine or 
ibuprofen, flat disc-shaped core tablets o f 7 mm diameter and 5 mm depth were 
compressed on a Manesty F3 single punch tabletting press as previously discussed in 
section 2.2.2.3. The hardness o f the core tablets were first measured on a Pharma Test 
PTB 311 hardness tester. The press was then adjusted to produce core tablets of 
approximate hardness o f 50 N/m2. Table 2.4.2 lists the composition o f the different 
cores that were compressed and used for the preliminary study.
The cores were then compressed together with the 10%w/w camauba wax in 
ethylcellulose cups to a depth o f 4 mm and not a specific hardness, as described 
previously in section 2.3.
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TABLE 2.4.2
Maximum time o f constant release (tmaJ  fo r  caffeine and ibuprofen from  different 
polymers
Polymer
Acacia % P E G - 
6000 %
T raga- 
canth%
HEC %
La* (hours) 
± S.D.
(n = 3)
Caffeine
5
5
5
5
7,513 ± 0 ,52  
3,720 ± 0 ,12  * 
1,083 ± 0 ,14  
3,597 ±0,31 *
10
Ibuprofen
10
10
10
11,523 ±0 ,447 
6,767 ± 0,049 # 
1,600 ± 0,292 
6,533 ± 0,249 #
5
5
5
5
18,380 ± 1,113 
12,390 ±0,399 
3,800 ± 0,096 * 
4,320 ±0,340 *
10
10
10
10
27,217 ± 1,775 
8,387 ± 0,497 
4,093 ±0,156 # 
5,103 ±0,190 #
*’* in a  vertical column indicate homogenous groups that show no significant 
difference at the 95% level o f  confidence using the LSD analysis o f variance test.
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Once it was established that acacia was most suitable for the release o f caffeine, 
and PEG 6000 was most suitable for the release o f ibuprofen, from the core-in-cup 
tablets, cores o f the compositions listed in table 2.4.3 were produced and compressed 
to a hardness o f 40, 50 or 60 N/m2. These were also compressed to a depth o f 4 mm 
together with the cup portion o f the tablet. The tabletting press was previously 
adjusted to  produce a tablet o f 4 mm thickness. Compressing the core and cup o f the 
tablet together to a 4 mm depth was just enough compression to compress the core 
and cup portion o f the tablet together without too adversely affecting the difference in 
hardness o f the core tablets.
2.4.2.4 Release Studies
The B.P. 1988 paddle method was utilised in all the release studies. A volume 
o f 1000 ml o f 0,1 M HC1 in deionized water, equilibrated at 37°C ± 0,5°C, was used 
as the release medium for the caffeine tablets. For the ibuprofen tablets, 1000 ml o f 0,2 
M phosphate buffer B.P. at a pH o f 7,2 and equilibrated at 37°C ±  0 ,5°C, was used. 
All experiments were carried out at 50 rpm. The release rates o f the tablets were 
monitored using a Caleva model 7ST dissolution tester connected to  a Beckman DU 
650 spectrophotom eter via a  flow-through cell. Dissolution medium was pumped 
through Elkay solvent flex PVC tubing (I.D. o f 0,1 inches) w ith bridge tubing at a rate 
o f 3,9 ml/min. by means o f a Desaga STA peristaltic pump. The bridge tubing was 
connected to  add  flexible manifold tubing which was connected to  the flow-cell, and 
also from the flow-cell back into the dissolution flask. In order to  constantly monitor 
the release o f the drugs, the spectrophotom eter was programmed to  read the 
concentration o f the drug in the flow cell at 10 minute intervals. Ibuprofen was 
measured spectrophotometrically at a wavelength o f 216 nm, while caffeine was 
measured at a wavelength o f242 nm. Linearity was established for 0,1 M HC1 aqueous 
solutions o f caffeine, and 0,2 M phosphate buffer aqueous solutions o f ibuprofen, in 
the range o f 6,25 - 200 pg/ml.
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2.4.2.7 Statistical analysis
Analysis o f variance was performed on the data presented in Table 2.4.3 using 
STATGRAPHICS v 5 (Statistical Graphics Corporation, U.S.A.). The independent 
variables were % polymer in the core tablet (c) and hardness o f the core tablet (/»), 
while the dependent variable was maximum time o f constant release (tmac) from the 
core-in-cup tablets. Response-surface plots were constructed for the above variables, 
in order to  determine the optimal combination o f the variables. Main effects and 
significant interactions were also calculated. Simple regression models for the two 
independent variables were also developed from the results as follows:
Y, (c,h) = a0 + a,c  + a jt  + a fh  + a /Y  + a /Y  - equation 2.4.1.
where a0l...,as are the coefficients o f the system, c and h denote the % polymer in the 
core tablet and hardness o f the core tablet, respectively.
Each term in the final regression equation for the maximum time o f constant 
release was only included if the /-test p  value was less than 0,05. The regression 
coefficients for those effects that were considered insignificant were eliminated and the 
model was re-estimated. All statistical analysis was performed using STATGRAPHICS 
v 5 (Statistical Graphics Corporation, U.S.A.).
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2.4.3 R esults and Discussion
Table 2.4.3 lists the tmax values for the release o f caffeine and ibuprofen from 
the different formulations tested.
TABLE 2.4.3
Maximum time o f constant release ft__) fo r  caffeine and ibuprofen (c, % polymer; h,
hardness;)
Run h c Mean hardness 
N/m2) ± SD
(n=3) m^ax (hours)
Caffeine Ibuprofen Caffeine Ibuprofen
1. -1 -1 38,16 ± 2 ,94 43,19 ± 3,33 4,17 12,83
l b -1 -1 45,99 ± 8 ,46 35,51 ± 7 ,82 4,00 11,17
2, -1 0 36,84 ± 4,43 41,06 ± 8,64 5,67 9,67
2b -1 0 43,07 ± 2,40 44,32 ± 5,55 7,33 6,83
3, -1 1 42,72 ± 4,94 42,80 ±5,11 10,67 6,83
3b -1 1 42,94 ±4 ,75 40,14 ± 7 ,20 11,83 6,00
4a 0 -1 52,24 ± 5 ,66 50,48 ± 3,98 6,33 11,00
\ 0 -1 54,55 ± 8,02 51,32 ± 6 ,46 5,83 12,67
5a 0 0 48,16 ± 4 ,14 48,00 ± 9 ,76 10,17 9,83
5b 0 0 51,60 ±7 ,85 53,21 ± 5,68 10,50 10,67
5C 0 0 48,81 ± 2 ,07 50,18 ± 9 ,29 11,33 10,33
5d 0 0 52,53 ± 5,96 53,67 ± 5,47 9,50 9,83
6a 0 1 49,76 ± 4 ,19 50,41 ± 5,80 13,33 6,67
6b 0 1 52,91 ± 7,88 51,13 ± 8 ,02 12,17 6,83
7a 1 -1 64,55 ± 9,95 64,40 ±6,91 7,83 15,33
7b 1 -1 58,27 ± 8,33 60,13 ± 8,47 8,83 14,33
8a 1 0 66,56 ±4,03 66,07 ± 4,09 11,83 8,00
8b 1 0 62,86 ± 6,41 62,44 ± 4 ,16 12,50 8,83
9a 1 1 68,62 ± 6 ,19 64,09 ± 3 ,27 14,83 7,33
9b 1 1 65,69 ± 7,43 60,26 ± 5,41 13,67 7,50
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Table 2.4.4 lists the relevant statistical parameters calculated from the results o f this 
study for the effect o f the two independent variables on the maximum time o f constant 
release (tmax) o f the core-in-cup tablets analyzed. All statistical analysis was carried out 
on all the experimental runs (total 20).
TABLE 2.4.4
Relevant statistical parameters
Source Estimated effects p-value Regression Regression
effect ± standard error coefficients coefficients
(13 d f ) re-estimated
Caffeine release from acacia
average
constant
10,040 ±0.381
-20,470 -7,837
c 6,583 ±0,512 < 0,001 1,211 0,658
h 4,358 ±0,512 < 0,001 0,629 0,218
ch -0,609 ± 0,627 0,359 -0,006
cc -0,619 ±0,825 0,474 -0,012
hh -0,700 ± 0,825 0,421 -0,003
Ibuprofen release from PEG 6000
average
constant
9,2863 ±0,514
4,775 15,626
c -6,028 ± 0,690 0,000 -0,735 -0,603
h 1,332 ± 0,690 0,076 0,381
ch -0,915 ±0,845 0,299 -0,009
cc 1,473 ± 1,113 0,208 0,029
hh -0,447 ±1,113 0,699 ■0,002
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2.4.3.1 Caffeine release from  acacia
Figure 2.4.1 is the response surface plot o f the estimated effects o f the % 
acacia and hardness o f the core tablet on the tmax o f caffeine from the core-in-cup 
tablets. Both the concentration o f acacia and the hardness o f the core tablet play a 
significant role in the resultant tmax o f the core-in-cup tablets. Concentration o f acacia 
in the core tablet has the most significant influence on its tmax (Fig. 2.4.1). Since the 
acacia acts as a binder for the caffeine this effect is expected.This binding efficiency is 
at its maximum when the compression force is increased, and the difference in the tmax 
at the higher compression force (equivalent to  a  hardness o f±  60 N/m2) is similar to 
that at the lower compression force (equivalent to  a  hardness o f ± 4 0  N/m2). The 
similarity in effect on the tmax is evidenced from the estimated main effects o f6,583 for 
c  and 4,358 for h. There were no significant (p  < 0,05) interaction effects from the % 
acacia and hardness o f the tablets on the rate o f release o f caffeine.
H ardness
Fig. 2.4.1 Response surface plots o f the estimated effects o f c and h on the tmax o f 
caffeine from the core-in-cup tablets.
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In developing a regression model for the effect o f the independent variables on 
the tmax dependent variable, only the main effects were significant (p < 0,05). 
Therefore, the regression coefficients for these effects were included in the model.
The rest o f the coefficients were eliminated and the model was re-estimated by 
STATGRAPHICS.
Ytc (c,h,) = -7,837 + 0,658c + 0,218h - equation 2.4.2
where Yte (c,h) is the estimated tmax o f caffeine from the core-in-cup tablets.
The squared multiple regression coefficient for this model was 0,949. This 
model shows that % concentration o f acacia in the core tablet has the major effect on 
the imax. As the concentration increases the tmm increases. The hardness o f compression 
also produces an increase in the tmax. Clearly, in order to  produce a core-in-cup tablet 
that needs to  release drug for a tmax o f approximately 8 - 1 2  hours the concentration of 
acacia and hardness o f  compression can be adjusted to  produce the required tmax.
2.4.3.2 Ibuprofen release from  PEG 6000
Figure 2.4.2 is a response surface plot o f the estimated effects o f the % PEG 
6000 and hardness o f the core tablet cup on the tmax o f ibuprofen from the core-in-cup 
tablets tested. Only the concentration o f PEG 6000 in the core tablet plays a significant 
role in the resultant o f the core-in-cup tablets (Fig. 2.4.2). Since the PEG 6000 is
w ater soluble it causes the ibuprofen to  be released at a quicker rate than if the 
ibuprofen were compressed on its own. As the concentration o f  PEG 6000 increases 
from 5 to  15%w/w, the quicker is the release from the core-in-cup tablets and the 
shorter is the The tmac times decreased from 15,33 hours to  6,83 hours, depending 
on the hardness o f compression o f  the core tablet. Hardness o f compression, on the
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other hand had very little significant effect on the release o f ibuprofen from the tablets. 
As the hardness increased from 40 N/m2 to  60 N/m2, the only increased on 
average, over all %  concentration levels o f PEG 6000, from 8,89 hours to  10,22 hours. 
The effect o f hardness o f compression on the tmax o f ibuprofen from PEG 6000 was 
even less pronounced at the 15%w/w PEG 6000 level. The tmac only increased on 
average from 6,42 hours to  7,42 hours. There were no significant ip  < 0,05) 
interaction effects from the % PEG 6000 and hardness o f the core tablets on the rate 
o f release o f ibuprofen.
In developing a regression model for the effect o f the independent variables on 
the tmac dependent variable, only the concentration o f PEG 6000 was significant ip < 
0,05). Therefore, the regression coefficient for this effect only, was included in the 
model. The rest o f the coefficients were eliminated and the model was re-estimated by 
STATGRAPHICS.
Yu (c,h,) = 15,626 - 0,603c - equation 2.4.3
where Yti (c,h) is the estimated tmax o f ibuprofen from the core-in-cup tablets.
The squared multiple regression coefficient for this model was 0,8659. This 
model shows that the % concentration o f PEG 6000 in the core tablet is the only factor 
that has a significant effect on the tmax. As the concentration increases the tmaK 
decreases. The hardness o f compression produces an increase in the tnaK) but not 
significantly enough. In order to  produce a core-in-cup tablet that needs to  release 
ibuprofen for a tm„ o f approximately 8 - 1 2  hours the concentration o f PEG 6000 can 
be adjusted to  produce the required tmca from equation 2.4.3 above.
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Fig. 2.4.2. Response surface plot o f the estimated effects o f c and h on the tmax o f 
ibuprofen from the core-in-cup tablets.
From the above results it can be seen, that it is possible to produce a core-in­
cup tablet that can release aqueous soluble (caffeine) and insoluble (ibuprofen) drugs at 
a zero-order rate, depending on the type o f erodible polymer used. For insoluble drugs, 
it is best to use an.aqueous soluble polymer such as PEG 6000, and for a soluble drug, 
it is best to use an erodible polymer like acacia. Neither PEG 6000 nor acacia swelled 
to  any noticeable extent in the aqueous dissolution fluid used and therefore, there was 
no splitting (which could lead to  dose dumping) o f the cup portion o f the core-in-cup 
tablet as can be the case with polymers that swell in aqueous fluids.
In the following section the in vitro dissolution rate o f the model drug 
theophylline in simulated gastrointestinal fluids from a core-in-cup system -mil be 
evaluated. Acacia will be used as the bioerodible sustained - release polymer in the 
core o f the tablet. As theophylline is a slightly aqueous soluble drug, acacia could be 
the most suitable polymer to use in the core o f the tablet. Various concentrations of
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acacia will be utilised, from which the ideal concentration o f acacia that should be 
added to the core o f the tablet to get a constant release o f theophylline over an 8 to 12 
hour period, will be determined.
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3 IN  VITRO ANALYSIS OF THE CORE-IN-CUP 
TABLETS
3.1 DISSOLUTION O F THEO PH Y LLIN E FRO M  CO RE-IN -CU P TABLETS 
IN  SIM ULATED G A STRIC AND INTESTINAL FLUID.
3.1.1 In troduction
Sustained release o f drugs in the gastrointestinal tract following oral 
administration is the intended rate - limiting factor in the absorption process and, in 
turn, the bioavailability and therapeutic response (Hussein and Friedman, 1990; Block 
and Banakar, 1988). It is therefore, essential in the development stages to  use 
dissolution methods that allow pharmacokinetic screening o f dosage forms, in 
particular, the prediction o f the absorption rate from sustained - release preparations. If 
one wants to  predict the in vivo release o f drugs from zero-order release systems from 
in vitro data, then it is important that one chooses a model that closely approximates 
the conditions in the gastrointestinal tract (Skelly et al., 1990; Amidon, et ai., 1995) 
for approximately 8 to 16 hours. It is also not sufficient to  test the release o f drugs in a 
single dissolution medium (Skelly et al., 1986a and b). One means o f effectively testing 
the in vitro release from a drug delivery system, is to  first test it in simulated gastric 
fluid, followed immediately by simulated intestinal fluid (Lin and Ayres, 1992; Whiting 
et al., 1991; Bodmeier and Paeratakul, 1989; Bodmeier et al., 1989). Ideally, the drug 
delivery system should release drug at a zero-order rate in both o f these simulated 
fluids for a time similar to  the gastrointestinal residence time. This time however, can 
be highly variable due to  many factors.
3.1.1.1 Gastrointestinal residence time.
After ingestion, an oral nondisintegrating dosage form will stay in the stomach 
for an unpredictable time. To understand the implications o f this initial state o f the GI
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transit, it is worth mentioning the role o f the stomach in terms o f its anatomical 
structure and m otor functioning during either the interdigestive or digestive phases 
(Code and M artlett, 1975; Kelly, 1980; Sama, 1985; Kellow et a l, 1986). During the 
interdigestive phase, the empty stomach displays a cyclic motion called the 
interdigestive migrating motor complex (IMMC). This cyclic motion can be divided 
into four phases as follows.
(1) Phase I - mostly an inactive phase with little or no contractions. It lasts up to  60 
minutes.
(2) Phase II - consists o f irregular and intermittent sweeping contractions.
(3) Phase III - acute eruptions o f peristaltic waves in distal and proximal gastric 
areas. It last 5 to  15 minutes. This is the phase that empties the stomach o f its 
fasting contents and indigestible debris. This is why it is almost impossible to  keep 
multiple-unit or monolithic dosage forms in the stomach (MUller-Lissner and Blum, 
1981; M ojaverian e ta l,  1985, 1987 and 1991; Davis, 1986).
(4) Phase IV  - conversion period o f decreasing activity until the next cycle.
This overall IMMC cycle lasts approximately 1,5 to  2,0 hours. The gastric residence 
time o f solid dosage forms is thus mainly dependent on the coincidence between 
dosing time and phase III IMMC occurrence. The gastric emptying is consequently 
rather unpredictable and the residence time is usually short and highly variable. 
However, the ingestion o f food interrupts the IMMC cycle (Thompson et al., 1980) 
and allows the digestive phase to  take place. Ingestion o f food also delays the delivery 
o f drugs to  the small intestine (Davis et a l , 1986). The degree o f delay depends on the 
type o f  formulation. Highly soluble drugs given in a  conventional dosage form or drugs 
given as pellets, disperse in the gastric fluids and are emptied w ith the food. 
Nondispersible single units are retained in the stomach until phase III o f the IMMC 
returns. Thus after a meal, the pylorus appears to  act as a sieve allowing small particles
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through but retaining larger particles (Meyer et al., 1981 and 1985; Gruber et al.,
1987; Itoh et al., 1986). This delay in the emptying o f large inert particles from the 
stomach has been utilized to  design drug delivery systems that are large enough to  be 
retained in the stomach for longer periods o f time (Cargill et al.). There is however, no 
exact cut-off size o f solid particles that would not be expelled until the IMMC arrival.
It is believed to  be larger than 3 to  7 mm in diameter (M eyer et al., 1985; Feldman et 
al., 1984). This is probably due to  interindividual variations in the diametral opening o f 
the pylorus and in the pressure force o f the propelling waves.
Numerous other factors may influence the gastric transit o f sustained-release 
drug delivery systems (Dressman et al., 1993). Among the stimulatory and inhibitory 
mechanisms that regulate the emptying rate o f a  meal, the characteristics o f the diet 
components have first to  be taken into account. These include acidity, osmolality, 
temperature, viscosity, volume, calorific contents, and relative fat, protein and 
carbohydrate concentration (Sheiner 1975).
The transit in the small intestine is more regular than in the stomach. As 
estimated from several studies, the mean expected transit duration o f a meal marker for 
95% o f the population lies around 2 to  4 hours (Davis et a l,  1986). This transit is 
remarkably constant, irrespective o f the presence o f food or the type o f drug delivery 
system.
Unlike the small intestine, the transit time in the colon is highly variable. Transit 
times vary from approximately 1 hour to  more than 60 hours (Hardy et al., 1985; 
M etcalf et al., 1987). Single unit drug delivery systems such as tablet matrices and 
capsules tend to  remain for prolonged periods o f several hours not only at the ileocecal 
junction before entering the colon, but also at the hepatic and splenic flexures o f the 
large bowel. They progress intermittently by acute thrusts o f movement separated by 
periods o f prolonged stasis (M etcalf et al., 1987).
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To sum up the physiological limitations discussed, it appears that the transit 
rate o f a drug delivery system in the GIT may be highly variable and dependant, 
amongst other factors, on its size and digestibility. The transit time can be as short as a 
few hours and as long as 2 o r 3 days. For this study, however, we will accept 8 to  16 
hours as the average transit time for a normal healthy adult. Therefore, an attempt will 
be made to  formulate a core-in-cup tablet that releases drug at a zero-order rate o f 
release in simulated gastrointestinal fluids for a period o f 8 to  16 hours.
3.1.1.2 Dissolution cmd bioequivalence.
In most cases, a drug must first pass into solution to  be absorbed through the 
GIT membrane. Drugs with low solubility are absorbed with difficulty through 
biological membranes, and with such compounds the rate o f dissolution in GIT fluids is 
universally the rate-controlling step for absorption. Dissolution is the process by which 
a chemical or drug becomes dissolved in a solvent (Sharget and Yu, 1993). In 
biological systems, drug dissolution in an aqueous medium is an important prior 
condition o f systemic absorption. The rate at which drugs w ith poor aqueous solubility 
(or sustained-release preparations) dissolve (or are released, for sustained-release 
preparations) from an intact or disintegrated solid dosage form in the GIT often 
controls the rate o f systemic absorption o f the drug. Therefore, it is important that 
research includes efforts to  develop in vitro tests that will be valid predictors o f 
bioavailability in humans. I f  in vitro dissolution properties for a  drug are found to  serve 
as a useful index o f in vivo absorption, the time, expense and difficulties o f clinical 
trials may be reduced o r eliminated. In some cases, in vivo bioavailability is not 
required by the Federal Drug Administration o f  the U.S.A., and only in vitro data is 
required for registration purposes (Stavchansky and McGinity, 1990). In vitro 
dissolution rate screening has been used (Barr, 1972; Barr and Adir, 1974; Barr et al., 
1972) as a sensitive quality control measure to  show changes in drug release for 
products undergoing variable storage conditions. It is also used to  warn o f poor 
bioavailability o f drugs from dosage forms that show erratic release patterns in 
comparative studies (Prasad eta l., 1983; Shah eta l., 1983; Levy, 1961; Levy, 1965;
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Bergan et a l, 1973; Gibaldi and Weintraub, 1970; W ood, 1966). Therefore, it is a 
valuable tool in formulation design and quality control and is a necessary test before in
vivo analysis is attempted.
3.1.1.3 In vitro dissolution testing and apparatus.
M ost pharmaceutical products go through a dissolution test during their 
development. Therefore, it is not unexpected that there are more than 100 apparatuses 
that have been suggested for the measurement o f in vitro drug release from solid drug 
delivery systems (Pamarowski, 1974; Baun and Walker, 1969; Swarbrick, 1970; 
Strieker, 1976). The many different types o f apparatus can be classified into three 
broad categories.
(a) Closed-compartment systems.
These systems usually have a large closed-compartment in which the 
dissolution fluid is placed. They employ large volumes o f dissolution fluid as 
they assimilate sink conditions. Some examples o f the equipment include the 
rotating basket (USP XXI), paddle method (BP 1980), rotating flask (Gibaldi 
and W eintraub, 1970), beaker method (Levy and Hayes, 1960), static disc 
(Levy, 1963), circulating flow-through cell (Baun and Walker, 1969), and spin 
filter (Shah et al., 1973).
(b) Open flaw-through systems.
Open flow through systems also use large volumes o f dissolution fluid, 
but only a small amount, is actually active in the dissolution process at any 
point in time. Therefore, most o f these apparatus are adaptations o f the closed- 
compartment models. Examples o f flow-through systems include the oscillating 
tube (Marshall and Brook, 1969), stationary basket (Shah and Ochs, 1974), 
and sintered filter (Tingstad and Riegelman, 1970).
91
(c) Dialysis and diffusion models.
In the diffusion models, dissolved drug passes through a membrane or 
dividing layer into a second compartment from which the drug is analyzed. 
Some examples o f these systems are the rotating basket (Marlow and 
Shangraw, 1967) and the rotating bottle (Barzilay and Hersey, 1968).
Each o f the above apparatuses have their own inherent advantages and 
disadvantages. No m atter what the specific advantages o f the apparatus are, it must 
meet the following criteria;
(a) The apparatus must be economically viable. It should be accomplished by the 
use o f standard laboratory equipment, so that it can be standardised as far as 
possible.
(b) The apparatus must be scientifically pragmatic. The inherent variability in the 
apparatus should be less than the inherent variability in the products being tested.
(c) The apparatus must be flexible in providing an effective degree o f agitation. One 
must be able to  alter the effective degree o f agitation by altering the rate o f 
agitation.
O f the above methods, the rotating basket and paddle methods are the only 
official oral drug delivery system methods in the USP and BP. They are both closed- 
compartment methods and comply well w ith the above criteria. Therefore, it is not 
surprising that these tw o methods are the m ost widely used methods for dissolution 
testing for research and quality control.
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The purpose o f this study is to  test the dissolution rate o f a standard model 
drug like theophylline from the core-in-cup tablets previously developed. In order for 
the test to  be relevant and reproducible it was decided that it would be best to  test the 
dissolution in the presence o f sequenced simulated gastrointestinal fluids in the BP 
paddle apparatus. The effect the sequenced simulated fluids on the zero-order rate o f 
release o f drug will also be tested. A prerequisite o f an effective core-in-cup system is 
that it must not be too affected by conditions in the GIT, and it should also be capable 
o f releasing drugs over a period o f at least 8 hours at a zero-order rate.
3.1.2 M aterials and M ethods
3.1.2.1 Materials
Acacia was supplied by Saarchem (Pty) Ltd, South Africa. The acacia had a 
viscosity o f 53 cps as a 4% aqueous solution at 23 °C. Theophylline anhydrous (Knoll 
AG, Germany) was ground in a m ortar and the fraction passing through a No. 150 
standard U K. sieve was used. Caffeine (Sigma Chemical Company, U.S.A.) as 
internal standard was used as supplied.
Pancreatin from porcine pancreas with an activity at least equal to  U.S.P. 
specifications, and pepsin from porcine stomach mucosa with 550 units/mg activity 
were obtained from Sigma Chemical Company, U.S.A. and were used as supplied. 
Sodium-1 -octanesulfonate and sodium-1 -heptanesulfonate were supplied by TCI-Ace, 
Tokyo Kasei Kogyo Company, Ltd., Japan. Ethylcellulose (Sigma Chemical Company, 
U.S.A.) and camauba wax (Sigma Chemical Company, U.S.A.) were also used as 
supplied. All other reagents used were standard laboratory grade.
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3.1.2.2 Formulations
Granules o f 10%w/vw, 20%w/w, and 30%w/w acacia with theophylline were made 
as previously described in section 2.2.2 3. The press was then adjusted to produce core 
tablets o f approximate hardness o f 40 N/m2 and thickness o f 5 mm. The average 
weights o f the core tablets and their standard deviations for each formulation are listed 
in table 3.1 below.
TABLE 3.1
Weights o f theophylline core formulations.
%w/w Acacia Weight o f core ± S.D. (n=10) Intended weight o f theophylline
10 158 ±8,367 142,2 mg
20 171 ± 10,035 136,8 mg
30 182 ± 11,612 127,4 mg
The theophylline cores were then compressed together with the 10%w/w 
camauba wax in ethylcellulose cups to a depth o f 4 mm as previously described in
section 2.2.2.3.
3.1.2.3 Dissolution Studies
The B.P. 1988 paddle method was utilised in all the dissolution studies. 
Dissolution rates o f the tablets were monitored using a Caleva model 7ST dissolution 
tester. A volume o f 1000 ml o f freshly prepared simulated gastric fluid TS U.S.P. XX 
was used as the dissolution medium during the first two hours, and then replaced by 
1000 mis o f freshly prepared simulated intestinal fluid TS U.S.P. XX for an additional 
10 hours. At time zero, a core-in-cup tablet was placed in the simulated gastric fluid
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equilibrated at 37°C ± 0,5°C. After tw o hours, the core-in-cup tablet was then 
carefully removed from the simulated gastric fluid and placed in simulated intestinal 
fluid pre-heated and equilibrated at 37°C ± 0,5°C  for a further 10 hours. All 
experiments were carried out at 50 rpm. One millilitre samples were withdrawn from 
the dissolution media for theophylline determination after various time intervals.
3.1.2.4 Theophylline analysis
Samples withdrawn from the dissolution media were first centrifuged for 20 
minutes at 5 200 r.p.m. to  remove the turbidity from the pancreatin and other insoluble 
particles. A 200 pi aliquot o f the clear supernatant was added to  200 pi o f a 0,02%w/v 
caffeine in distilled w ater internal standard solution. Theophylline/intemal standard 
ratios in the 400 pi solutions were analyzed on a 15cm Beckman ultrasphere ODS 5 
pm column connected to a Beckman System Gold HPLC consisting o f a 126 
programmable solvent module and 168 diode array detector module. Analytical 
wavelength was set at 280 nm. The mobile phase was perfused through the column at 
1 ml/min and consisted o f 95%v/v 0,02 M  sodium acetate buffer adjusted to  pH = 4,0 
with concentrated acetic acid, as well as 0,5 %w/v sodium-1 -heptanesulfonate, 0,5%w/v 
sodium-1-octanesulfonate, and 5%v/v propan-l-ol (added to  sharpen the 
chromatographic peaks). Chromatograms for theophylline and caffeine (internal 
standard) were completed within 10 minutes. Quantification o f theophylline levels 
were based on comparison to  standard solution curves in simulated gastric and 
intestinal fluid TS. The detection limit using this method was approximately 0,2 pg/ml 
theophylline.
3.1.2.5 Data analysis
To check that the theophylline was releasing from the core-in-cup tablets at a zero- 
order rate o f release and hence a zero-order rate o f dissolution, the cumulative amount 
o f theophylline from both gastrointestinal solutions at various time intervals were fitted 
to  zero-order, first-order, and square root o f time models. In order to  produce a
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cumulative amount o f theophylline released in sequenced simulated fluids, the amount 
released after 120 minutes was added to the amount released in the simulated intestinal 
fluid. These rates were then used to caluculate the amount o f acacia to be added to  the 
tablets that would would be able to  release theophylline over a period o f 12 hours. The 
correlation o f the dissolution rate with each model was then calculated. The model 
with the highest correlation coefficient (Pearson's coefficient) was accepted as the 
model that best describes the rate o f dissolution. The correlation coefficients for each 
model were then subjected to a LSD analysis o f variance test, to  check whether there 
was a significant difference (at the 95% level) between the correlation coefficients o f 
the models applied to  the data.
3.1.3 Results and Discussion
The dissolution o f theophylline from the core-in-cup tablets was fairly 
consistent in both simulated fluids. Figure 3.1 graphically describes the dissolution o f 
theophylline from the core-in-cup tablets over an 8 hour period from the sequenced 
simulated gastric and intestinal fluids. The theophylline was released and dissolved 
from the core-in-cup tablets at a rate that is more consistent with a zero-order 
dissolution rate than a first-order dissolution rate in both simulated fluids. There is no 
significant difference, as indicated by the LSD analysis o f variance test, between the 
correlation coefficients o f the zero-order and square root o f time models applied to  the 
data. There is, however a statistical difference between the zero-order and first-order 
models. Dissolution rates and the corresponding correlation coefficients o f the 
dissolution o f theophylline for zero-order, square root o f time, and first-order 
dissolution models from the various simulated fluids, are listed in table 3.2 below. 
Dissolution o f theophylline in the simulated gastric fluid TS is at a slightly lower rate 
than in simulated intestinal fluid TS. The dissolution (based on zero-order dissolution) 
o f theophylline from the 10%, 20% and 30% acacia core-in-cup tablets were 0,8742 
mg/min., 0,5255 mg/min., and 0,2688 mg/min., respectively in simulated gastric fluid 
TS, and 0,6114 mg/min., 0,3004 mg/min., and 0,2047 mg/min., respectively in
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TABLE 3.2
Dissolution model exponents, correlation coefficients and dissolution rates o f 
theophylline in various simulated media.
Acacia Order o f Correlation n for best Rate o f
(%w/w) model coefficient model ± S.D. dissolution.
used ± S.D. (n=3) (n=3) ± S.D. (n=3)
Simulated gastric flu id  TS
10 zero 0,998 ± 0,002 0,973 ± 0,052 0,874 ± 0,096
first 0,980 ± 0,008
f t 0,992 ± 0,005
20 zero 0,992 ±0,011 1,047 ±0,046 0,526 ± 0,093
first 0,941 ± 0,038
f t 0,982 ±0,013
30 zero 0,997 ± 0,002 1,033 ±0,020 0,269 ± 0,028
first 0,969 ±0,015
f t 0,996 ± 0,000
Simulated intestinalfluid TS
10 zero 0,989 ± 0,009 1,008 ± 0,024 0,611 ±0,102
first 0,986 ±0,012
f t 0,972 ± 0,036
20 zero 0,968 ± 0,023 0,300 ± 0,029
first 0,959 ± 0,042
f t 0,986 ±0,011 1,058 ±0,174
30 zero 0,992 ± 0,003 1,021 ± 0,028 0,204 ± 0,022
first 0,948 ± 0,029
f t 0,989 ± 0,008
Simulated gastric and intestinal flu id  TS
10 zero 0,996 ± 0,002 1,026 ±0,027 0,701 ± 0,193
first 0,970 ± 0,002
f t 0,996 ± 0,002
20 zero 0,989 ± 0,009 1,150 ±0,098 0,388 ± 0,042
first 0,915 ±0,033
f t 0,988 ± 0,004
30 zero 0,993 ± 0,002 1,161 ±0,065 0,224 ± 0,027
first 0,907 ±0,010
f t 0,988 ± 0,007
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Fig. 3.1 Dissolution of theophylline from core-in-cup tablets in simulated 
gastrointestinal fluids.
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simulated intestinal fluid TS. This is probably due to  the fact that theophylline is 
slightly more soluble in acidic medium than it is in alkaline medium. This increase in 
the solubility o f the embedded theophylline in the acacia makes the core portion o f the 
tablet erode at a slightly increased rate.
The increased erosion rate then leads to  an increase in the release o f 
theophylline with a resultant increase in the rate o f dissolution. Since the release o f 
theophylline from the core-in-cup tablet is slower than the rate o f dissolution, it 
appears that the rate o f release is the rate controlling step. Therefore, this core-in-cup 
system is a good system for zero-order release o f theophylline. The acacia does not 
seem to  have any effect on the zero-order rate o f dissolution. All three concentrations 
tested released theophylline at a zero-order rate o f release. It also has the ability to 
release theophylline at a zero-order rate for a  prolonged period o f time, depending on 
the concentration o f acacia used.
If  one starts with a theophylline concentration o f 100 mg (the intended dosage 
to be given to beagle dogs in the in vivo analysis o f the core-in-cup tablets) in the core 
o f the tablet, and wants it to  be released over a period o f 12 hours the rate o f release 
would have to be 0,1389 mg/min. Therefore, the optimal concentration o f acacia can 
be calculated by substituting this rate (the rate that releases drug over a period o f 12 
hours) into equation 3.1 and then solve for the concentration o f acacia needed.
C = 37,7842 - 40,6217 X R - equation 3.1.
where, R  = zero-order release rate (from overall dissolution data) o f 
theophylline from core-in-cup tablets in mg/min.
C = % w/w concentration o f acacia.
Equation 3.1 was obtained from the linear regression o f the zero-order combined 
dissolution (cumulative release in gastric and intestinal fluid) rates versus concentration
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o f acacia used in the core-in-cup tablets to  produce those rates. The square o f the 
correlation coefficient for this linear relationship was 0,9688. Solving equation 3.1 then 
gives a value o f 32,1418 for the % 7W acacia to add to the theophylline to  release 
theophylline at a rate o f 0,1389 mg/ min. in simulated gastric fluid TS for 2 hours 
followed by simulated intestinal fluid TS for 10 hours.
Therefore, in the next section, core-in-cup tablets with a concentration o f 
lOOmg theophylline and 30% 7W acacia will be produced, and then tested in vivo using 
Beagle dogs. A 30% 7W acacia concentration instead o f a 32,1418% 7W acacia 
concentration, was used so that it was possible to  develop an in vivo to in vitro 
correlation. During the in vitro analysis a 30% 7W acacia in theophylline concentration 
was used for the dissolution studies. The ability o f the core-in-cup tablets to  release 
drug at a zero-order rate with a resultant zero-order rate o f absorption will also be 
checked, as well as a number o f important pharmacokinetic parameters that will 
indicate the effectiveness o f the core-in-cup tablet as a zero-order controlled release 
drug delivery system.
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4. IN  VIVO ANALYSIS OF THE CORE-IN-CUP 
TABLETS
4 1 IN  VIVO  ANALYSIS O F THEO PH Y LLIN E CO RE-IN -CU P TABLETS IN 
BEAGLE DOGS.
4.1.1. In troduction
The ideal controlled-release formulation is one which releases the drug at a 
constant rate, associated with a constant rate o f absorption and producing sustained 
therapeutic concentrations over a prolonged period o f time (Silber et a l, 1988). This 
period o f time, should be preferably over an entire dosing interval. Therefore, the 
purpose o f a controlled release drug delivery system is to  improve therapy by 
maintaining uniform plasma concentrations at steady state, by reducing the ratio o f 
maximum and minimum plasma concentrations (Theeuwes and Bayne, 1977).
Although a thorough in vitro analysis is an important step in the formulation o f new 
drug delivery systems, and it can supply the formulator with good relevant information, 
an in vivo analysis is always necessary. Conditions in the GIT are never ever really the 
same as those that can be simulated. Important pharmacokinetic parameters like rate o f 
absorption, peak plasma concentration, extent o f availability, elimination rate, and 
many other important parameters can only be obtained from in vivo studies. Therefore, 
it is always important in the development o f drug delivery systems to  conduct a 
thorough in vivo analysis. An in vivo analysis is necessary for the validation o f in vitro 
models, specifically if  one would like to develop an in vitro/in vivo correlation, so that 
the in vitro model can be used for further formulation studies.
4.1.1.1 Criteria to assess in vivo performance o f sustained-release products
Many different criteria have been used to assess the performance o f sustained- 
release drug delivery systems. Basically, from a pharmacokinetic point o f view, a good
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controlled-release drug delivery system should release drug at a zero-order rate for as 
long as is possible to  maintain a level therapeutic plasma drug concentration. 
Therefore, the rate o f absorption and peak drug level characteristics such as peak 
plasma time and plasma drug fluctuation are the major in vivo pharmacokinetic 
properties o f drug delivery systems that need to  be analyzed. The following are some 
o f the many different parameters that have been suggested to  evaluate the in vivo 
absorption and peak drug level characteristics o f controlled-release drug delivery 
systems.
(a) Assessment o f  absorption rate
The three classical pharmacokinetic parameters used to  assess 
bioequivalence; area under the curve (AUC), maximum plasma concentration 
(Cmax) and the time taken to  maximum plasma concentration (/max), are 
suitable to  determine the extent and rate o f absorption o f immediate release 
drug delivery systems. However, they are not very useful in evaluating the 
pharmacokinetic performance, particularly the rate o f absorption o f controlled- 
release formulations (Bialer, 1995).
AUC is currently the ruling criterion to characterise the extent o f 
absorption and to  assess bioequivalence o f standard and controlled release 
formulations (Welling, 1983; Dighe and Adams, 1988). AUC is a strong 
parameter which takes into account all the experimental points collected in 
each period o f a bioequivalence study. It is not very likely that a new 
pharmacokinetic standard will substitute AUC for representation and 
assessment o f extent o f absorption. The exact selection o f the proper 
pharmacokinetic criteria to  assess the rate o f absorption o f controlled-release 
formulations is still uncertain. Cmax and /max are single experimental point 
parameters which are not much use in cases o f level or multiple peak 
concentration-time curves, as is often the case from controlled-release 
formulations. In addition, when Cmax and /max are determined by visual
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inspection o f the data, they depend on the sample schedule times. The more 
readings one takes around Cmax, the more accurate the readings will be. Cmax 
is also unfortunately, affected by changes in the extent o f absorption.
Because o f the above limitations o f Cmax and /max, the following 
pharmacokinetic parameters and criteria have been considered to  characterise 
rate o f absorption o f controlled-release products.
(1) Mean absorption time (MAT)
The statistical moment method o f analysis for the blood level profiles 
considers the time course o f in vivo drug concentrations as a statistical 
distribution function o f time (Cutler, 1978; Yamaoka et al., 1978; Riegelman 
and Collier, 1980). The first moment estimates the mean residence time (MRT) 
o f a drug which is calculated from equation 4.1.
MRT = AUMC - equation 4.1
AUC
W here AUMC is the area under the moment curve which is obtained by 
means o f calculating the area under the curve o f the plasma concentration 
multiplied by the corresponding time versus the time o f measurement o f plasma 
drug level.
Like AUC, MRT is also a strong parameter which takes into 
consideration all the experimental points in each phase o f the study. Since the 
MRT estimates relate to  both the rate and extent o f absorption, they are useful 
in evaluating in vivo performance o f controlled-release drug delivery systems 
(Lin and Yang, 1988; Block and Banakar, 1988).
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If  one compares the MRT o f a test formulation with the MRT o f a 
formulation that is immediately absorbed (an IV dosage form), then the mean 
absorption time (MAT) can be calculated from equation 4.2.
MAT = M R T ^  - MRT* - equation 4.2
The MRT* basically reflects the distribution and elimination rates in the 
body, and therefore, the difference between M R T ^ and MRT* is an estimation 
o f the in vivo absorption rate o f the drug from the test formulation. In some 
cases IV data is not available and an MRT for a solution may be calculated.
The mean dissolution time (MDT) or an in vivo mean dissolution time for a 
solid product is given in equation 4.3 (Gillespie et al., 1982; Graffner et 
al., 1984).
MDT = M R T ^ - MRT^**^ - equation 4.3
MDT reflects the time for a drug to  dissolve in vivo. Despite its usefulness, 
MRT has not yet gained widespread acceptability.
(2) In vivo mass balance absorption rate
The mass balance method is based on the additivity o f the amounts o f 
drug already excreted or still at the site o f absorption, in the central 
compartment (including the sampling department) and, possibly, in the 
peripheral compartment. One o f the earliest methods for the estimation o f the 
absorption o f a  drug into the blood was developed by W agner and Nelson 
(W agner and Nelson, 1963,1964). This technique was based on the 
assumption that the body is a  angle compartment from which the drug is 
eliminated by first-order processes. Either urinary o r blood data can be 
collected. The method has gained wide acceptance because it does not require
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prior estimate o f the apparent volume o f distribution and places no limitations 
on the order o f the absorption rate constant. Equation 4.4 was derived by 
W agner and Nelson for estimation o f the percentage absorption o f drug from a 
drug delivery system up until time T.
where, Ar is the cumulative amount o f drug absorbed from time zero to 
time T. A . is the amount eventually absorbed. K is the overall 
elimination rate constant. Cr is blood, serum, o r plasma concentration 
at time T.
The method using blood level data is as follows: Successive values o f 
the top right hand side o f equation 4.4 are calculated from the time o f 
administration (t = 0) to some time after the peak in the blood time plot. The 
area under the curve for each value can be calculated using the trapezoidal rule 
or any other convenient method. The cumulative values o f the top o f the right 
hand side o f equation 4.4 progressively increase, then reach a maximum or 
asymptotic value. When the individual values are expressed as percentages o f 
the maximum or asymptotic value, the results are percent absorbed values to 
various times T. I f  the cumulative percentages absorbed are plotted against 
time, the resulting plots may contain linear segments up until the asymptotic 
value; the slope o f such a linear segment is the absorption rate in percent per 
time unit, i.e. zero-order rate absorption. I f  the log o f cumulative percentage 
absorbed up until the asymptotic value versus time is linear then a first-order 
rate o f absorption can be suspected. The W agner and Nelson method is 
particularly useful in determining the relative efficiency o f absorption o f a drug 
from different oral formulations for demonstrating in vitro to  in vivo 
correlations (W einberger et al., 1981; Gonzalez and Golub, 1983; Chung and
% absorbed = Ar X 100 = 
A .
X 100 - equation 4.4
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Shim, 1987; Aiache eta l., 1989; Hussein and Friedman, 1990).
Loo and Riegelman (1968) developed a method o f calculating the % 
drug absorbed from a two-compartment model. Their model, described by 
equation 4.5, is based on the assumption that a drug upon oral or intravenous 
administration confers upon the body the characteristics o f a two-compartment 
model.
where, C1T is the concentration o f drug in the central compartment at 
time T, and C2T is the concentration o f drug in the peripheral 
compartment at time T.
This method has not gained popularity amongst researchers, as it 
requires that the drug is given intravenously in order to  estimate the apparent 
volume o f distribution and the overall elimination rate constant. An estimate o f 
the amount o f drug in the peripheral compartment as a function o f time after 
oral administration must also be made on the same subject under carefully 
replicated conditions.
(3) Deconvolution methods
Another in vivo mass balance technique that has gamed popularity in 
the past few years has been the numerical deconvolution technique (Vaughn 
and Dennis, 1978; Langenbucher, 1982). The numerical deconvolution 
methods do not assume a specific compartmental model but merely linearity 
and time invariance o f the disposition kinetics (Tucker, 1983). The disposition
% absorbed = Ar  X 100 =
A..
CiT + C27- +
- equation 4.5
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kinetics are usually derived from a reference experiment with intravenous 
administration. Deconvolution methods reconstruct the concentration - time 
curve after oral administration (input function) o f drug from the concentration - 
time curve after IV administration (response function). The input function can 
be considered as the cumulative distribution function after IV bolus dose, the 
superposition o f which results in the concentration - time curve after oral 
administration.
As the deconvolution methods calculate the absorption rate in the w-th 
time interval on the basis o f approximations in preceding time intervals, the 
choice o f appropriate times o f measurement is extremely important. Errors in 
the first value are carried over to  all subsequent values. In view o f this problem, 
numerical smoothing is frequently applied prior to  deconvolution, which can 
become very subjective depending on the smoothing technique used.
(b) Plateau Time.
D ata on ta ax  and summarising statistics are only explicit if  Cmax is 
obvious and described by abundant measurements in the close vicinity o f Cmax. 
In the case o f level and multiple plasma maxima, which occur with controlled- 
release formulations, the plateau time is a more robust characteristic than finax. 
The plateau time could be defined as the time span o f one dosing series during 
which the serum concentration deviates from the maximum concentration by 
less than a clinically specified difference or percentage. In the case o f a 50% 
deviation from the maximum, the plateau time corresponds to the half - value 
duration (M eier et a l, 1974). Some authors (Jonkman et al., 1981) believe that 
a 50% deviation is too large and believe that it should only be a 20% (Jonkman 
eta l., 1981) or 25% (Steinijans e ta i, 1987;Bialer, 1995).
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No m atter which percentage deviation is used, the longer the plateau time, the better 
the strength o f the retardation o f the release from the controlled-release product, and 
the less often the drug needs to  be dosed.
(c) Percent peak - trough fluctuation.
In the case o f flat or multiple maxima blood level profiles, ftnax and 
Cmax are o f limited value. A better measure o f the controlled-release 
characteristics in these cases, would be to  describe the peak - trough variation 
that exists in the steady-state blood level versus time profile o f the drug. This 
can be done by expressing the residual concentration at the end o f the dosing 
interval, once the drug has reached steady-state, in percent o f either the 
maximum or the average concentration (refer to  equations 4.6 and 4.7).
% PTF = 100 X (Cmax - Cmin) - equation 4.6
Cav
% Swing = 100 X (Cmax - Cminl - equation 4.7
Cmin
where %PTF is the % peak - trough fluctuation; Cmax, Cmin and Cav 
are the maximum, minimum and average plasma drug concentration 
within the dosing interval at steady state, respectively.
Unfortunately, equations 4.6 and 4.7 are reliant on a single 
measurement and its potential error. To prevent this reliance on a single 
measurement, the percentage area under the curve fluctuation (% AUCF) 
around Cav is a robust measure o f the fluctuation o f plasma concentration 
(S tein ijanse/a/., 1987; Boxenbaum, 1984). Calculation o f %AUCF is 
described in equation 4.8.
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%AUCF = 100 X  AUC (Above Cavl + AUC (Below Cavl
AUC - equation 4.8
Unlike %PTF and % Swing, the %AUCF takes into account o f all values o f the 
plasma concentration versus time curve at steady state within a dosing interval.
Two important pharmacokinetic parameters o f controlled-release are the rate 
o f absorption and the time o f controlled release. The purpose o f this study therefore, is 
to  conduct an in vivo pharmacokinetic study o f theophylline model drug from the core­
in-cup tablet in Beagle dogs. Pharmacokinetic parameters that will be studied include, 
elimination rate, rate and kinetic order o f absorption, relative availability as compared 
to an immediate release capsule o f pure theophylline, and %AUCF at steady state.
4.1.2 M aterials and  M ethods
4.1.2.1 Materials
Acacia was supplied by Saarchem (Pty) Ltd, South Africa. The acacia had a viscosity 
o f 53 cps as a 4% aqueous solution at 23 °C. Theophylline anhydrous (Knoll AG, 
Germany) and caffeine (Sigma Chemical Company, U  S A .) were ground in a mortar 
and the fraction passing through a No. 150 standard U.K. sieve was used.
Sodium-1 -octanesulfonate and sodium-1-heptanesulfonate were supplied by TCI-Ace, 
Tokyo Kasei Kogyo Company, Ltd., Japan. Ethylcellulose (Riedel de-Haen, South 
Africa) and camauba wax (Sigma Chemical Company, U.S.A.) were also used as 
supplied. All other reagents used were standard laboratory grade.
4.1.2.2 Formulations
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Three different types o f dosage forms o f theophylline were used in the in vivo 
study. Capsules containing lOOmg pure theophylline were prepared by means o f 
separately weighing out lOOmg theophylline and filling size 2 capsules. The capsules 
were used as the immediate release dosage form from which the elimination rate could 
be calculated. Its blood profile was also used to determine the relative extent o f 
bioavailability o f the core-in-cup tablets. Core-in-cup and core only tablets containing 
53,846mg (35% w/w) acacia and lOOmg theophylline per tablet were also prepared and 
made as previously described.
4.1.2.3 Drug administration and sample collection.
Five female adult Beagle dogs, clinically healthy and hematologically normal, 
weighing between 16 and 22Kg, were used in this study. Each o f the three dosage 
forms were given to  each dog separately after a 14 day 'wash out' period, over a period 
o f three months. Food, but not water, was withheld for 12 hours before and after drug 
administration. Dosing o f each dog was staggered at 15 minute intervals so as to 
facilitate subsequent blood sampling. Oral administration o f the drug delivery systems 
was achieved by opening the mouth o f the dog, depressing the tongue, placing the 
drug delivery system in the throat region with subsequent administration o f about 100 
ml o f water. The mouth was firmly closed and air was blown through the dog's nose in 
order to  facilitate swallowing (Gangadharan et a l, 1987). Blood samples (4 - 5 ml) 
were withdrawn from the jugular vein at 0, 0,5, 1, 2, 4, 6, 8 ,10 ,16  and 24 hours. The 
blood samples were allowed to stand for 1 hour, centrifuged at 4 100 r.p.m. in a 
Hettich E.B.A. Ill centrifuge (Tuttlingen, Germany) for 15 minutes, and then stored at 
4°C until analysis. All samples were analyzed within 48 hours from collection. The 
faeces o f each dog was collected and checked for the presence o f the cup portion o f 
the tablet.
4.1.2 .4 Theophylline extraction and analysis
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The extraction and subsequent HPLC analysis o f theophylline and its major 
metabolites from blood samples is well documented in both human (Yuen et al., 1993; 
Tanaka, 1992; Blanchard et al., 1990; Chiou et al., 1987; Chung and Shim, 1987) and 
animal studies (Davis et al., 1993; Parra and Limon, 1991; Hussein and Friedman, 
1990; McKieman et al., 1981). It is by far the best method for analysis o f theophylline 
from blood plasma, from an expense, accuracy and reliability point o f view (Moncrieff, 
1991). M ost extraction procedures from blood plasma involve the co-elution o f 
theophylline and its internal standard into an organic solvent/plasma protein aqueous 
precipitator mixture o f solvents. The most common solvent combination used is a 
chloroform/isopropyl alcohol mixture. Therefore, the following extraction procedure 
was used for both the blood samples and spiked samples for standard curve 
preparation:
(1) A 1 ml sample o f blood plasma was mixed with 1 ml o f caffeine internal 
standard solution (5 pg/ml) on a vortex mixer for 1 minute.
(2) 3 ml chloroform and 1 ml isopropyl alcohol was then added to this mixture, 
vortexed for 1 minute and then centrifuged for 10 minutes at 5 200 r.p.m.
(3) The aqueous (upper) layer was carefully aspirated off, and 1 ml was 
withdrawn from the chloroform layer, transferred to  a clean conical glass tube, 
and evaporated to  dryness in a waterbath set at 37°C, under a gentle stream o f 
nitrogen gas.
(4) The dry residue was reconstituted w ith 200 pi mobile phase, vortexed for 1 
minute, and then analyzed via HPLC.
In order to  construct the standard curves, plasma from fresh beagle dog blood 
was collected and immediately spiked with known concentrations o f theophylline. 
Theophylline aqueous solutions o f 30 gg/ml serially diluted to  1,875 pg/ml were 
prepared. 3 mis o f plasma was then spiked with 1 ml o f each o f the standard solutions
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and then mixed thoroughly. Plasma, instead o f blood was spiked, because it was 
impossible to  accurately measure out an exact volume o f blood for the standard 
samples. The standard plasma solutions then resulted in a concentration range o f 
theophylline from 7,5 pg/ml to  0,4688 pg/ml after dilution with the plasma, which 
were used to construct the standard curves and calculate the accuracy and 
reproducibility o f the method. Theophylline and caffeine internal standard were then 
extracted and prepared for analysis as described above. The accuracy and 
reproducibility from spiked drug-free plasma were calculated from concentrations o f
7.5 pg/ml, 1,875 pg/ml and 0,4688 pg/ml o f theophylline in plasma by comparing the 
peak-height ratio against internal standard with those obtained for aqueous solutions 
containing known concentrations o f theophylline. The mean extracted concentrations 
(n = 3 ±  s.d.) calculated on the basis o f peak-height ratios against the internal standard 
were 7,1576 ± 0,7157 pg/ml, 1,4868 ±0,1891 pg/ml and 0,4854 ± 0,1009 pg/ml for 
the 7,5 pg/ml, 1,875 pg/ml and 0,4688 pg/ml spiked plasma solution o f theophylline, 
respectively.
The theophylline concentration in the extracted blood samples and standard 
solutions from spiked plasma were assayed on an HPLC system as previously 
described under section 3.2.4.
4.1.2.5 Data analysis.
The plasma concentration/time curves for the core-in-cup and core only 
systems were analyzed to  estimate the rate o f absorption, the % AUCF and the relative 
extent o f availability (%RA).
The rate o f absorption was estimated from the Wagner-Nelson method 
discussed above. These rates o f absorption for each dog and drug delivery system were 
then checked to  see how well they fit either a zero - order (plasma concentration 
versus time), first - order (logarithm o f plasma concentration versus time), or square 
root o f  time (plasma concentration versus square root o f time) model. The applicability
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o f each model was done by calculating its correlation coefficient from the fraction of 
theophylline absorbed from time zero to 4 hours (the linear portions o f the fraction 
absorbed versus time plots). The results from each dog were analyzed separately, 
because there is usually quite a large subject to subject variation in the blood levels o f 
theophylline, as well as the fact that the dogs were not dosed on a quantity per kg 
basis. The elimination rate used to calculate the fraction o f drug absorbed for each time 
interval in equation 4.4 was estimated from the last section (time 10 to 24 hours) o f the 
plasma concentration/time curve after the immediate release capsule dose.
To estimate the %AUCF at steady state, the plasma concentrations after a 
single dose were extrapolated to the time interval between 50 hours and 60 hours 
using the method o f superposition (Gibaldi and Perrier, 1982; Koritz et al., 1986) 
based on a 10 hour dosing interval. Plasma concentrations o f theophylline after a single 
dose that were spoiled due to breaking o f centrifuge tubes, or those values that were 
extraordinary, were smoothed graphically before they were extrapolated to  the time 
interval between 50 and 60 hours. This was done to  enhance the accuracy o f the 
method. The concentration remaining at each time interval (Cr) from the previous 
intended dosage (the dosage regime that one would give to  a  patient until steady state 
is reached) was calculated from equation 4.9. This equation is based on the first order 
elimination rate calculated previously.
Kg (T - T-l )  + lnCr.j
Cr = e -equation 4.9
The estimated values o f plasma concentration at steady state were based on a dosing 
interval o f 10 hours. This shorter dosing interval from the predicted 12 hour dosing 
interval, was used as the gastrointestinal transit time o f dogs is shorter than that o f 
humans (Bialer et al., 1988). To calculate the %AUCF below and above the average 
plasma concentration, the intersection point o f the graph at the average plasma 
concentration level was estimated graphically. To test whether there is a significant
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difference between the core only and core-in-cup drug delivery systems, a single paired 
- sample hypothesis test at a 95% confidence interval was tested on the difference in 
the parameter that was measured. A single paired - sample hypothesis test is used 
because the two drug delivery systems were each given to  each dog in the study as a 
cross-over regimen. In order to check whether there is an in vitro dissolution///? vivo 
absorption rate correlation, the correlation coefficient o f the fraction o f theophylline 
dissolved in vitro from the 30%w/w acacia in theophylline versus the in vivo fraction of 
theophylline absorbed from the core-in-cup tablets was calculated. The fractions 
dissolved or absorbed were calculated at the times o f 0,5, 1 , 2 , 4 , 6  and 8 hours.
4.1.3 R esults and Discussion
Figures 4. la  to  4. le  show the theophylline plasma concentrations o f the three 
dosage forms given to each dog. The extrapolated theophylline plasma concentrations 
to the steady state time interval o f 50 to  60 hours is also shown.
Time (hours)
-  € >  - C ore only — ©—  C ore-in-cup C apsule
Fig. 4.1a Theophylline plasma concentrations from capsules, core only tablets and
core-in-cup tablets in Nola.
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T im e (hours)
- - £ ) - •  C o re  only — © -  C o re -in -cu p  — Capsul e
Fig. 4 .1b  Theophylline plasma concentrations from capsules, core only tablets and 
core-in-cup tablets in April.
T im e (hours)
- - 0 - -  C o re  only — 6—  C o re -in -cu p  — •■ -* C apsule
Fig. 4 .1 c  Theophylline plasma concentrations from capsules, core only tablets and
core-in-cup tablets in Lorraine.
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Fig. 4. Id  Theophylline plasma concentrations from capsules, core only tablets and 
core-in-cup tablets in Lynne.
T im e (hours)
- • £ ) - •  C o re  only — ©—  C o re -in -cu p  — Capsul e
Fig. 4 .1 e  Theophylline plasma concentrations from capsules, core only tablets and
core-in-cup tablets in Prue.
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As can be seen from the graphs, there is quite a large variation in the plasma 
concentrations from dog to  dog. The variation, however, between the three dosage 
forms in each dog is much more consistent. This is also the case with the elimination 
rate calculated from the capsule dosage form, which varies from 0,1223 hr'1 to 0,1803 
h r1.
Table 4.1 lists the results from the calculation o f the relevant parameters o f 
AUC, %AUCF, %RA and the correlation coefficients from each model for the 
absorption o f theophylline, from the core only and core-in-cup tablets. Theophylline 
from both the core-in-cup and core only tablets was absorbed in vivo at a rate that is 
best described by a zero-order model. This is evidenced from the higher correlation 
coefficients for the zero-order model. The only exception was that for the dog Nola, 
where a square root o f time model was most applicable with a square root o f time 
correlation coefficient o f 0,9979 as compared to  the zero-order rate correlation 
coefficient o f 0,9887. Even though the absorption o f theophylline from the core only 
and core-in-cup tablets were both best described by the zero-order rate model, the 
correlation coefficient for this model was significantly higher (p = 0,0314) for the 
core-in-cup tablet. The zero-order rate model mean correlation coefficient for the core 
only and core-in-cup tablets were 0,9902 ± 0,0034 and 0,9952 ± 0,0017. Therefore, 
one can conclude that the core-in-cup tablet is better at releasing theophylline in vivo 
at a  zero-order rate than the uncoated core only tablet. This result, o f course is 
consistent with that predicted from the in vitro dissolution rate done in the previous 
experiment.
Although the average %AUCF for the core-in-cup tablet was less than that 
from the core only tablet, the difference o f 6,9334 was not quite significant at the 95% 
level. The probability o f a significant difference was p  = 0,0545. This is probably due 
to the %AUCF for the core-in-cup tablet given to  one o f the dogs (April) was slightly 
greater than that for the core only tablet.
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TABLE 4.1
Relevant statistical and pharmacokinetic parameters o f the in - vivo theophylline 
analysis from  capsules, core only tablets and core-in-cup tablets.
Parameter 
Mass (Kg)
Nola
19,7
April
14,7
Lorra­
ine
19,0
Lynne
11,6
Prue
13,5
Mean ± S.D.
Capsules
AUC 146,89 139,21 144,83 134,64 135,70 140,25 ± 4,86
Ke (hr'1) 0,1803 0,1400 0,1446 0,1555 0,1223 0,1485 ±0,0192
Core only
AUC 166,02 132,84 126,15 139,91 134,58 129,90 ± 8,21
%AUCF 15,49 12,69 19,97 15,65 17,14 16,19 ±2,37
%RA 78,99 95,43 87,10 103,91 99,17 92,92 ± 8,88
Order o f release correlation coefficient 
0-order 0,9887 0,9875 0,9963 0,9870 0,9917 0,9902 ±0,0034
1-order 0,9218 0,8943 0,9034 0,8553 0,8922 0,8934 ±0,0217
f t 0,9979 0,9447 0,9875 0,9669 0,9881 0,9770 ±0,0191
Core-in-cup
AUC 61,27 51,51 98,02 81,03 117,98 81,96 ±24,13
%AUCF 8,81 15,40 8,02 7,38 6,67 9,26 ±3,15
%RA 41,71 37,00 67,68 60,18 86,94 58,70 ±18,11
Order o f release correlation coefficient 
0-order 0,9938 0,9957 0,9955 0,9930 0,9980 0,9952 ± 0,0017
1-order 0,8931 0,9403 0,9309 0,9229 0,9295 0,9233 ±0,0161
f t 0,9494 0,9689 0,9526 0,9580 0,9673 0,9592 ± 0,0078
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As could be expected, the %RA o f theophylline from the core only and core-in­
cup tablets were significantly different (p = 0,0147). There was also quite a large 
variation in the AUC and hence %RA from animal to animal. The difference in the 
%RA o f theophylline from the core only and core-in-cup tablets was due to the 
average short gastrointestinal transit time o f the dogs.
In three o f the five dogs, a cup tablet with a small amount o f remaining core, was 
found in the faeces o f the dogs. The intact cups were found after 6 hours for Nola and 
after 8 hours for April and Lynne. The empty cups for the two remaining dogs were 
found in the faeces some time after 16 hours. For all the dogs, the cup portion o f the 
core-in-cup tablet was defecated intact. The only visible change to the cups were a 
slight rounding off and erosion around the edges o f the cups. These 12 mm diameter 
core-in-cup tablets should not have a problem passing through the human pylorus. 
Ashford et al (1993) produced a nondisintegrating 10 mm tablet which was then 
coated with a pH sensitive polymer, to  check on the tablets transit time to  reach the 
human colon. Through radioimaging techniques, they found that the intact tablet easily 
passed through the fasted stomach into the intestine:
Fig. 4.2 Fraction o f theophylline released into simulated gastrointestinal solution in 
vitro from the core-in-cup tablets versus the fraction o f theophylline absorbed in vivo 
at various time intervals.
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Figure 4.2 is a plot o f the fraction o f theophylline released into simulated 
gastrointestinal solution in vitro from the core-in-cup tablets versus the fraction o f 
theophylline absorbed in vivo at various time intervals. The results o f correlation 
obtained from the linear regression analysis between the fraction dissolved in vitro and 
fraction absorbed in vivo are presented in table 4.2.
The correlation slope values listed in table 4.2 indicate that the absorption o f 
drug in vivo in dogs is on average 27,64% slower than the rate o f dissolution in vitro 
in simulated gastrointestinal fluid. The mean slope was 0,7236 ± 0,012. Variability o f 
the slopes in the in vivo to  in vitro correlation, however, was very low. Slopes varied 
from 0,7136 to  0,7404.
TABLE 4.2
The in vivo to  in vitro correlation parameters for the Beagle dogs obtained by linear 
regression analysis from the 30% w/w core-in-cup tablets.
Names o f Beagles
Nola April Lorra- Lynne Prue Mean ± S.D.
ine
Slope
Correlation
0,7386 0,7228 0,7194 0,7404 0,7136 0,7236 ± 0,012
coeffic­
ient
0,9625 0,9603 0,9829 0,9919 0,9968 0,9789 ±0,017
Therefore, the correlation between the in vitro dissolution rate in simulated 
gastrointestinal fluid and the in vivo absorption rate is very strong for theophylline 
from the core-in-cup tablets in Beagle dogs. However, care must be taken in 
extrapolating this correlation to  humans. Only once effective human studies have been 
conducted, can one make the correlation from in vitro data.
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5. DISCUSSION
The core-in-cup oral tablet developed throughout this research is an effective 
and versatile drug delivery system for releasing drugs at a zero-order rate o f release. 
This has been established from in vitro and in vivo release studies.
S .l. Conclusion.
The core-in-cup system released a number o f different drugs at a rate that was 
much closer to zero-order than the release from a core only matrix system. This was 
confirmed by the better correlation coefficients obtained from the fitting o f the zero- 
order model as compared to the first-order or 'square root o f time' models. The core­
in-cup system also released a number o f drugs o f varying solubility properties. It 
released ibuprofen (insoluble), caffeine (soluble) and theophylline (intermediate) from 
the core-in-cup tablets at zero-order rates o f  release. Therefore, it could be posable to 
accommodate almost any drug that needs to  be released at a  controlled rate in the GIT. 
As long as the drug is formulated in a soluble polymer that erodes at a zero-order rate. 
This is possible since there are quite a number o f different polymers available which 
vary according to  their solubility and erosion in aqueous medium.
The core-in-cup tablet is also simple to  manufacture. All that is required is a 
special adjustable punch (as has been described in this research) which fits to  any 
Manesty tabletting press. Punches specific to  other tabletting presses can also easily be 
manufactured. The adjustable punch is versatile in that it can vary the mass o f the core 
tablet that can be manufactured and therefore, the hardness and compression weight o f 
the tablet can be regulated as is the case for any other regular tablet.
During this research, the cores were placed by hand in the ready made cups, 
and then compressed together. In order to  fully automate the core-in-cup tablet 
production, it would require an elementary adaptation to  the tabletting press, from
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which the cores can be fed into the cups and then fed sequentially into the final 
compression die. On the other hand, the cores and cups could first be produced on 
separate tabletting presses. Then, the cores could be fed via a tube feeder into the cups 
and fed into the press for final compression.
The final ethylcellulose and camauba wax combination, used to  manufacture 
the cup portion o f the tablet, is directly compressible and has good flow and 
compressibility properties. This powder combination, also retains its shape and 
integrity throughout the release o f the drug, and was defaecated with ease by the 
beagle dogs. It was found that a combination o f 10%w/w camauba wax in ethylcellulose 
(average particle size o f 925 pm) was the best combination for good compressibility 
and flow properties.
When considering the duration o f drug release from the core-in-cup tablets, it 
was found that by the careful selection o f the type o f polymer, polymer g rade, and the 
hardness o f compression, it is possible to  produce a  tablet that can virtually release 
drug for any period up to  24 hours. This was the case for both soluble and insoluble 
drugs. The type o f polymer had the most significant effect on the release rate. The 
results showed that polyethylene glycol 6000 was most suitable for ibuprofen and 
acacia was most suitable for caffeine and theophylline. Next, concentration o f polymer 
and hardness o f compression had the most significant effect on the release rate 
respectively. The release properties, type o f polymer, concentration o f polymer, and 
hardness o f  compression varies from polymer to  polymer. Thus each o f these 
properties would have to  be tested for each new polymer that one contemplates to  use.
5.2 R ecom m endations
The new adjustable punch and the core-in-cup system does open up a number 
o f new opportunities in drug delivery. The core-in-cup tablet can be adapted to  
produced an immediate release component and a sustained-release component to  the 
tablet. Two cores, one with the immediate release component and the other with the
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sustained-release component can compressed as a multilayer core tablet into the cup 
tablet to  produce a multilayer core-in-cup tablet. This type o f system would be most 
suitable for the cores formulated with HPMC, which swells predominantly in the 
vertical direction. The immediate release component would be dissolved immediately 
and would then relinquish space within the cup for the HPMC to swell. This concept is 
graphically described in figure 6.1.
Fig. 6.1 Core-in-cup tablet with an immediate release component
In a similar manner, a pulsed-release tablet can be produced using different 
polymers in the layers o f the core that are designed to release after predetermined 
times. The concentration o f drug in each layer can also be varied. A zero-order enteric 
release core-in-cup tablet can also simply be formulated by way o f making the top 
layer o f the core from cellulose acetate phthallate, for example.
IMMEDIATE RELEASE DISC
DISINTERGRATED 
IMMEDIATE RELEASE DISC
HOLLOW  CUP TABLET I n e r t  c u p  t a b l e t
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If the adjustable punch with the inner rod is used as the lower punch in the 
tabletting press and a similar punch without the inner rod is used as the top punch, it 
could be possible to  manufacture a doughnut - shaped tablet with a neat large central 
hole. This would eliminate the wastage o f drug when a hole is drilled in the centre o f 
the tablet as reported by Kim (1995). Many tablets must also be wasted when they 
crack during drilling.
Presently, the cup portion o f the core-in-cup tablet is formulated not to 
disintegrate or fundamentally change its shape during its journey through the GIT. 
Therefore, once the cup portion o f the tablet has moved throughout the GIT, it is 
defaecated unchanged. As the cup portion o f the tablet increases in size (which might 
be required from drugs which require a larger dose and hence larger punches to 
produce them), it could become a problem during defaecation o f the tablet from the 
GIT. Consequently, it would be desirable that the cup portion o f the tablet was 
designed to disintegrate once it had released the drug from it. This leaves two 
possibilities.
(1) The first is to  formulate a cup tablet that starts to  erode only once it enters the 
colon. Since the human colon has a high concentration o f the anaerobic bacteria o f 
the Bacteroides species (Simon and Gorbach, 1984) which have the ability to  
ferment many mucopolysaccharides and nonstarch polysaccharides (Cummings and 
Englyst, 1987; Bingham, 1987), it could be possible to  use a polymer that is 
degraded by these bacteria, to  achieve this end. Rubenstein and coworkers 
(Rubenstein et al., 1993) have produced a calcium pectinate tablet that released 
indomethacin in the presence o f  pectinolytic enzymes and also in die presence o f 
Bacteroides ovatus. Using calcium pectinate for the cup portion o f the core-in-cup 
tablet, could possibly result in the cup portion o f the tablet being degraded only once 
it enters the colon.
(2) The second way o f formulating a cup tablet that disintegrates once it has
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released its drug load, is to  formulate the cup portion o f the tablet so that it erodes 
at a rate that is slower than the rate o f release o f the drug. This can be achieved by 
way o f utilising different grades o f polymer that erode at a substantially slower rate 
than that o f the core o f the tablet. By means o f careful formulation, the core could 
first release its active drug before the cup portion changes its shape on subsequent 
erosion.
Besides being applicable to  a broad range o f drugs, the core-in-cup drug 
delivery system is also applicable to  an implantable tablet. A core-in-cup implantable 
tablet utilising different viscosity grades o f polylactic glycollic acid (Resomer*, 
Boehringer Ingelheim KG, Germany) has been formulated, and released a combination 
o f levodopa and carbidopa simultaneously in vitro for a period o f up to  100 days 
(Danckwerts and van der W att, 1995). The cores o f the tablet were compressed from 
granular Resomer* RG 756 (i.v. o f 0,8) and Resomer* RG  858 (i.v. o f 1,4). The cups 
o f the core-in-cup tablet were compressed from granular Resomer8 L 207 (i.v. o f 1,6). 
M ost o f the levodopa and carbidopa was released before the cup portion o f the tablet 
was bioeroded to  lactic and glycollic acid. It is also envisaged that this implantable 
core-in-cup system could be applicable to  many other drugs that are characteristically 
released from an implantable system.
Therefore, the core-in-cup drug delivery system developed throughout this 
research is versatile and can be used for many different types o f drugs and novel 
dosage forms. It is simple to  produce on a large scale, and presents a number o f unique 
possibilities for formulation o f controlled - release drug delivery systems.
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